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Abstract
Cette thèse s’intéresse aux mécanismes de défense de la muqueuse
nasosinusienne au cours des principales maladies chroniques des voies
respiratoires supérieures, à savoir la rhinosinusite chronique avec et sans
polypes, ainsi que la rhinite allergique, par comparaison avec les maladies
chroniques des voies respiratoires inférieures comme l’asthme et la BPCO. La
question principale de ce travail est de savoir si les modifications épithéliales
observées au préalable dans les maladies chroniques des voies aériennes
inférieures (asthme et BPCO) se retrouvent également au niveau voies aériennes
supérieures. Le système de l’IgA sécrétoire y est exploré au travers de son
récepteur principal, le récepteur aux immunoglobulines polymériques (pIgR),
dont la production et l’expression s’avèrent être diminuées dans les maladies
liées à l’inflammation éosinophilique. Dans un deuxième temps, c’est l’épithélium
nasosinusien lui-même qui est investigu�...
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Summary 
Chronic inflammatory diseases of the upper airways represent an important 
health burden, with major impacts on medical costs and public health1, 2. 
These inflammatory disorders are associated with abnormal responses to 
environmental factors and involve interactions between multiple factors. 
Despite active research in the field, fundamental mechanisms underlying the 
pathobiology of these disorders remain elusive. 
Allergic rhinitis is clinically defined as a symptomatic disorder of the nose 
induced after allergen exposure by an IgE-mediated inflammation and 
considered as a classic Th2-mediated disease3. 17 to 29% of the European 
population suffers from allergic rhinitis, and prevalence as incidence are still 
increasing1,4. Chronic rhinosinusitis (CRS) seems to mirror the increasing 
frequency of allergic rhinitis, with an overall prevalence estimated around 
11% in Europe5, 6. CRS is defined as an inflammatory disorder of the upper 
airways, which undergo distinct structural and functional changes of the 
sinonasal mucosa. At one time considered as a single disease entity, CRS is 
now commonly subdivided into 2 subtypes with differing pathophysiology, 
clinical expression and responses to treatment: CRS without nasal polyps 
(CRSsNP) and CRS with nasal polyps (CRSwNP)2. A variety of 
inflammatory mediators, including cytokines and chemokines, as well as 
adhesion molecules and matrix metalloproteinases, are upregulated in both 
subgroups of CRS, as is remodelling7. The tissue inflammatory response in 
CRSsNP is known to be neutrophilic with a Th1 skewing and high levels of 
IFN-gamma, whereas CRSwNP inflammatory responses are characterized 
by eosinophilia with a tendency toward Th2 polarization, high local IgE 
concentrations, IL-4, IL-5 and IL-13 expression8.  
 Several specialized epithelial cells line the upper airways, playing a role 
both as mediators and regulators of immune and inflammatory response. 
The respiratory epithelium is continuously in contact with inflammatory and 
physical environmental stimuli, and provides frontline innate defence 
mechanisms, through a mechanical barrier function (mucociliary clearance) 
and the secretion of protective proteins9. Indeed, under physiological 
conditions, microorganisms are eliminated from the airways without 
involvement of the adaptive immune system. An impaired epithelial 
immune barrier function could thus be one of the causative mechanisms in 
CRS, compromising the pathogen-host interaction, making the sinonasal 
mucosa more susceptible to antigenic exposure and thereby leading to 
chronic inflammation10, 11. Indeed, these protective functions have been 
shown to be diminished in CRSwNP, allowing microbial colonization by 
Staph Aureus within the nose and sinus cavities12.  
A large spectrum of other alterations involving histology, T-cell patterns, 
remodeling parameters (eg, TGF-b), eicosanoid and IgE production, 
microorganisms, and epithelial barrier malfunctions has been reported to 
describe the pathogenesis of CRS11.  
Evidence of epithelial dysfunction in CRS has been described at different 
levels. First, the physical epithelial barrier is compromised or disarrayed. 
This defect may facilitate the passage of allergens and other foreign agents 
into the airway tissue, leading to immune activation and thereby further 
stimulating the inflammatory process. This has been shown in vitro13 as in 
vivo, in human14 and animal models15. 
It has also been shown that the chemical epithelial barrier was altered, with 
a modified number of mucus-producing goblet cells 16, 17, altered antioxidant 
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levels18 and changes in the airway surface liquid which contains various 
proteins and peptides that provide an antimicrobial shield; these include 
lysozyme, lactoferrin, secretory leukocyte proteinase inhibitor, elafin, 
secretory phospholipase A2, anionic peptides, cathelicidin and β-
defensins19. 
Finally, the immunological epithelial barrier has been shown to be modified, 
with various cytokines that are either upregulated or downregulated. This 
will be discussed in details in the first chapter. 
CRS results thus, at least in part, from a dysfunction of the nasal epithelium 
in its ability to orchestrate appropriate and regulated immune responses to 
foreign matter.20 As an implied corollary, defects in the mechanical barrier 
and innate immune response would result in appropriate recruitment and 
persistence of adaptive immune responses with development of the clinical 
symptoms characteristic of the disease.20 
 
A major frontline defense mechanism, common to the different mucosal 
surfaces, consists of secretory immunoglobulin A (s-IgA). IgA is the most 
abundant Ig isotype in nasal secretions, and produced by mucosal plasma 
cells, after what it is transported across mucosal epithelial cells. This 
transport is mediated by a transmembrane glycoprotein called the polymeric 
immunoglobulin receptor (pIgR). After transcytosis, IgA is released at the 
apical surface after proteolytic cleavage of the pIgR extracellular domain 
known as secretory component (SC). 
 
The first aim of this work was to investigate whether the active transport of 
IgA was affected in chronic sinonasal pathologies, through a reduced 
 expression of pIgR in the nasal mucosa, as described previously in the 
bronchial epithelium of severe COPD patients21. Indeed, we observed a 
reduction of the pIgR expression in CRS, but unexpectedly in the CRSwNP 
phenotype, as well as in AR (and not in CRSsNP). This defect was 
associated with decreased SC and IgA antibodies to bacterial antigens in 
nasal secretions of CRSwNP patients, in parallel to subepithelial 
accumulation of IgA, and related to eosinophilic, Th2-related inflammation.  
 
 
Figure 1 : Normal upper airways epithelium 
 
In addition to inflammation, it is increasingly evident that structural changes 
are present in chronic upper and lower airway diseases, as referred to as 
remodelling22, 23. Tissue remodelling in upper airways includes increased 
extracellular matrix deposition and subepithelial basement membrane 
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thickening23. A particular mechanism of remodeling and epithelial 
differentiation is represented by epithelial-to-mesenchymal transition 
(EMT), consisting of the loss of the epithelial phenotype by epithelial cells 
and acquisition of a mesenchymal phenotype24. EMT has been identified in 
the lower airways from patients with COPD24 and asthma25. Whereas 
features of EMT have been reported in chronic upper airway diseases13, 26-28, 
its existence in the upper airways has not been demonstrated yet. 
Since our team showed recently that pIgR downregulation is closely related 
in COPD to altered airway epithelial cell differentiation through TGF-β 
activation, thereby resulting in impaired lung IgA immunity in these 
patients29,  we wondered whether pIgR downregulation in CRSwNP could 
be due to de-differentiation of the upper airway epithelium.  
The second aim of this work was thus to assess whether epithelial 
dedifferentiation via EMT occurs in CRSwNP. We show that the sinonasal 
epithelium undergoes dedifferentiation towards a more mesenchymal 
phenotype in CRS, and that this occurs independently of CRS phenotype 
(CRSwNP and CRSsNP) and of lineage specification into ciliated and 
goblet cells.  
A third aim was to assess whether IgA responses could be modulated upon 
therapy, such as antibiotics, corticosteroids, anti-IgE or anti-IL5 
biotherapies. Therefore, we assessed different subclasses of IgA antibodies 
in CRSwNP patients treated by omalizumab or mepolizumab, as well as 
doxycycline and methyprednisolone, as compared to placebo. Only very 
modest differences were observed in these data, reinforcing the need for 
further studies looking at effects of therapies on local IgA production.  
 Finally, the main question of this thesis is to know if the epithelial 
modifications observed previously in chronic diseases of the lung, namely 
asthma and COPD, could also be found at the upper level of the airways, 
during chronic sinonasal diseases.  
Thus this thesis explores the pathobiology of the upper airway epithelium in 
chronic rhinosinusitis and shows that it undergoes important changes 
including pIgR downregulation and dedifferentiation through mesenchymal 
transition, also further highlighting common features of epithelial 
reprogramming in chronic disorders of both upper and lower airways.   
Summary 
21 
 
References 
 
1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on 
Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, 
GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl 86: 8-160. 
 
2. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on 
rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 
2012; 50(1): 1-12. 
 
3. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on 
Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, 
GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl 86: 8-160. 
 
4. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in 
Europe. Eur Respir J 2004; 24(5): 758-64. 
 
5. Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe--an 
underestimated disease. A GA(2)LEN study. Allergy 2011; 66(9): 1216-23. 
 
6. Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and nasal 
polyps 2007. Rhinol Suppl 2007; (20): 1-136. 
 
7. Pawankar R, Nonaka M. Inflammatory mechanisms and remodeling in chronic 
rhinosinusitis and nasal polyps. Current allergy and asthma reports 2007; 7(3): 202-8. 
 
8. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by 
measurement of inflammatory mediators. Allergy 2006; 61(11): 1280-9. 
 
9. Knight DA, Holgate ST. The airway epithelium: structural and functional 
properties in health and disease. Respirology 2003; 8(4): 432-46. 
 
10. Tieu DD, Kern RC, Schleimer RP. Alterations in epithelial barrier function and 
host defense responses in chronic rhinosinusitis. The Journal of allergy and clinical 
immunology 2009; 124(1): 37-42. 
 
11. Van Crombruggen K, Zhang N, Gevaert P, Tomassen P, Bachert C. Pathogenesis 
of chronic rhinosinusitis: inflammation. The Journal of allergy and clinical immunology 
2011; 128(4): 728-32. 
 
12. Van Zele T, Gevaert P, Watelet JB, et al. Staphylococcus aureus colonization and 
IgE antibody formation to enterotoxins is increased in nasal polyposis. The Journal of 
allergy and clinical immunology 2004; 114(4): 981-3. 
 
13. Soyka MB, Wawrzyniak P, Eiwegger T, et al. Defective epithelial barrier in 
chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL-4. The 
Journal of allergy and clinical immunology 2012; 130(5): 1087-96 e10. 
  
14. Ponikau JU, Sherris DA, Kephart GM, et al. Features of airway remodeling and 
eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to 
asthma? The Journal of allergy and clinical immunology 2003; 112(5): 877-82. 
 
15. Jacob A, Faddis BT, Chole RA. Chronic bacterial rhinosinusitis: description of a 
mouse model. Archives of otolaryngology--head & neck surgery 2001; 127(6): 657-64. 
 
16. Ding GQ, Zheng CQ. The expression of MUC5AC and MUC5B mucin genes in 
the mucosa of chronic rhinosinusitis and nasal polyposis. American journal of rhinology 
2007; 21(3): 359-66. 
 
17. Martinez-Anton A, Debolos C, Garrido M, et al. Mucin genes have different 
expression patterns in healthy and diseased upper airway mucosa. Clinical and 
experimental allergy : journal of the British Society for Allergy and Clinical Immunology 
2006; 36(4): 448-57. 
 
18. Carraro S, Cutrone C, Cardarelli C, Zanconato S, Baraldi E. Clinical application of 
nasal nitric oxide measurement. International journal of immunopathology and 
pharmacology 2010; 23(1 Suppl): 50-2. 
 
19. Travis SM, Singh PK, Welsh MJ. Antimicrobial peptides and proteins in the innate 
defense of the airway surface. Current opinion in immunology 2001; 13(1): 89-95. 
 
20. Schleimer RP, Kato A, Peters A, et al. Epithelium, inflammation, and immunity in 
the upper airways of humans: studies in chronic rhinosinusitis. Proceedings of the 
American Thoracic Society 2009; 6(3): 288-94. 
 
21. Pilette C, Godding V, Kiss R, et al. Reduced epithelial expression of secretory 
component in small airways correlates with airflow obstruction in chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med 2001; 163(1): 185-94. 
 
22. Puchelle E, Zahm JM, Tournier JM, Coraux C. Airway epithelial repair, 
regeneration, and remodeling after injury in chronic obstructive pulmonary disease. Proc 
Am Thorac Soc 2006; 3(8): 726-33. 
 
23. Watelet JB, Van Zele T, Gjomarkaj M, et al. Tissue remodelling in upper airways: 
where is the link with lower airway remodelling? Allergy 2006; 61(11): 1249-58. 
 
24. Pain M, Bermudez O, Lacoste P, et al. Tissue remodelling in chronic bronchial 
diseases: from the epithelial to mesenchymal phenotype. European respiratory review : an 
official journal of the European Respiratory Society 2014; 23(131): 118-30. 
 
25. Johnson JR, Roos A, Berg T, Nord M, Fuxe J. Chronic respiratory aeroallergen 
exposure in mice induces epithelial-mesenchymal transition in the large airways. PLoS One 
2011; 6(1): e16175. 
 
Summary 
23 
 
26. Henriquez OA, Den Beste K, Hoddeson EK, Parkos CA, Nusrat A, Wise SK. 
House dust mite allergen Der p 1 effects on sinonasal epithelial tight junctions. 
International forum of allergy & rhinology 2013; 3(8): 630-5. 
 
27. Meng J, Zhou P, Liu Y, et al. The development of nasal polyp disease involves 
early nasal mucosal inflammation and remodelling. PloS one 2013; 8(12): e82373. 
 
28. Shin HW, Cho K, Kim DW, et al. Hypoxia-inducible factor 1 mediates nasal 
polypogenesis by inducing epithelial-to-mesenchymal transition. American journal of 
respiratory and critical care medicine 2012; 185(9): 944-54. 
 
29. Gohy ST, Detry BR, Lecocq M, et al. Polymeric Immunoglobulin Receptor Down-
regulation in Chronic Obstructive Pulmonary Disease. Persistence in the Cultured 
Epithelium and Role of Transforming Growth Factor-beta. American journal of respiratory 
and critical care medicine 2014; 190(5): 509-21. 
 

     
 
   
 
 
CHAPTER 1: INTRODUCTION 
Immune defence mechanisms: comparing upper and lower 
airways in chronic airway diseases

Introduction 
 
 
27 
 
Immune defence mechanisms: comparing upper and lower airways in 
chronic airway diseases  
Cloé Hupin, Philippe Rombaux, Marylène Lecocq, Birgit Weynand, Yves 
Sibille, Charles Pilette, Immunology, Endocrine and Metabolic Agents – 
Medicinal Chemistry 2010; 10 (3):123-141 
 
ABSTRACT 
Several epidemiological, pathophysiologic and clinical data demonstrate the 
interrelationship between upper and lower airways, and common features 
between inflammatory pathways and disorders of the nasal and bronchial 
mucosa have been emphasized both in the clinic (ARIA guidelines1) and in 
basic science, and reflected by numerous reviews on this topic. In contrast, 
detailed comparative analysis of basic defence mechanisms in upper versus 
lower airways and its clinical relevance is lacking. 
It is becoming increasingly clear that airway epithelium plays a key role in 
driving key initiating steps of immune defence (either protective or 
deleterious) against inhaled antigens and particles. Epithelial cells respond 
to changes in the external environment by secreting a large array of 
antimicrobial host defence molecules, cytokines and chemokines following 
exposure to and activation by pathogen molecular patterns, and link in 
concert with dendritic cells innate to antigen-specific adaptive immunity. 
However, the type of epithelial response to ‘pathogens’ and danger signals 
may differ between upper and lower airways, as well as according to genetic 
background. 
    
 
 
 
This review provides an updated, extensive and comparative review of 
immune defence mechanisms of the respiratory tract, in upper versus lower 
airways, including most relevant changes observed during chronic airway 
diseases and how these may translate into different clinical features. 
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INTRODUCTION 
The airway epithelial cells work as a complex physical barrier but also play 
a crucial role in initiating and perpetuating airway host defence 
mechanisms. Mechanical defences include the deposition on the nasal and 
oropharyngeal surfaces and elimination through cough, sneezing and 
mucociliary clearance2. If particles or microorganisms reach the alveolar 
space despite these mechanical defences, alveolar macrophages insure their 
removal. Moreover, epithelial cells mediate innate host defence through 
production of antimicrobial molecules including antimicrobial peptides, pro-
inflammatory cytokines, growth factors, enzymes and chemokines3.  The 
production of these substances is initiated in response to activation via 
pattern recognition receptors (PRR)3. When the innate immune functions 
fail, the epithelium also induces the transition from innate immunity to 
adaptive immunity. Epithelial cells are capable of directing dendritic cells 
towards a response to antigen exposure4 and contribute to the local 
recruitment of phagocytes and antigen-specific T- and B-cells of the 
adaptive immune system, to eliminate the infection5.  
An increasing number of studies defend the concept of United Airways, 
suggesting that nasal and bronchial mucosa should be seen as a continuum, 
in particular in inflammatory reactions where inflammation in one part of 
the airway influences its counterpart at distance.  
Although much of the immunopathology is shared between the upper and 
lower airways, there are marked differences in the pattern of inflammation 
in the respiratory tract, with different inflammatory cells, mediators, 
consequences, and responses to therapy. 
    
 
 
 
Figure 1. Differences between upper and lower airways.  Whereas the epithelium shares 
several features, the nose originates from the ectoderm while lungs from endoderm. The 
immune system includes in upper airways the NALT, while immune cells do not display 
constitutively such organisation in the lower airways. Upper airways are physiologically in 
close contact with commensal microbes, while distal airways are supposed to be sterile. 
The structure of upper airways includes a large supply of subepithelial capillaries, arterial 
systems and venous cavernous sinusoids, while smooth muscle is only present in the 
bronchi. Finally, upper and lower airways differ by their physical function: sneezing, air 
warming, and deposition of large particles are properties of upper airways while cough and 
deposition of smaller particles occur in lower airways; both levels sharing mucociliary 
clearance as common physical defence.  
GC, goblet cell; IEL, intraepithelial lymphocyte; MC, mast cell; VE, vessels; SC, stem cell; 
DC, dendritic cell; BC, B cell; TC, T cell; APC, antigen presenting cell; PC, plasma cell; 
NALT, nasal associated lymphoid tissue; BALT, bronchial associated lymphoid tissue; 
BaC, basal cell 
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1. CLINICAL DEFINITION AND IMMUNOPATHOLOGY OF CHRONIC AIRWAY 
DISEASES 
Airway inflammation is observed in a wide range of respiratory conditions 
affecting upper and/or lower airways, which are caused or influenced by 
several components including genetic background (e.g., α1-antiproteinase 
deficiency, ADAM-33 polymorphism) and environmental exposure 
(allergens, microbes, irritants such as cigarette smoke). Some are closely 
linked to atopy (allergic rhinitis and asthma) and others to cigarette smoke 
(COPD). 
a. Allergic rhinitis 
Allergic rhinitis (AR) is an IgE-mediated inflammatory disorder due to 
abnormal responses of the nasal mucosa to inhaled allergens, characterized 
by a mixed inflammatory infiltrate made up of eosinophils, T cells (of the 
Th2 phenotype), mast cells and basophils6. Symptoms include sneezing, 
anterior or posterior aqueous rhinorrhea, nasal itching and nasal obstruction, 
on exposure to sensitizing antigens. AR affects patients of all ages, all 
countries, all ethnic groups and all socioeconomic conditions1, with a 
prevalence rate ranging from 17 to 29% in Europe7.  Ocular symptoms have 
been estimated to be present in 40–60% of the allergic population8. Ocular 
symptoms may present in allergic rhinitis, and less frequently may be  
associated in asthmatic patients8.  
b. Chronic rhinosinusitis 
Chronic rhinosinusitis (CRS) is characterized by persistent symptoms (more 
than 12 weeks) related to inflammation in the paranasal sinuses, defined 
    
 
 
 
clinically and on CT and/or endoscopic evaluation. Depending on the 
presence of polyps on endoscopy, CRS can be divided into CRS with nasal 
polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). CRSwNP and 
CRSsNP share most of their clinical features –with smell loss characteristic 
of NP, but these two entities may be distinguished by their respective T-cell 
cytokine profiles. CRSwNP displays Th2 polarization with IL-5 expression, 
eosinophilic infiltrate, and high local IgE concentrations, while CRSsNP is 
considered as Th1-biased, with high levels of IFN-γ9. 
Table 1 summarizes the recent definition proposed by the EAACI10. 
 
Inflammation of the nose and paranasal sinuses characterized by: 
- 2 or more symptoms, one of which should be either nasal obstruction or discharge :  
• Nasal blockage, congestion 
• Nasal discharge or postnasal drip 
• Facial pain or pressure 
• Reduction or loss of smell 
- And either 
• Endoscopic signs 
- Polyps and/or 
- Mucopurulent discharge from middle meatus and/or 
- Oedema/mucosal obstruction primarily in middle meatus 
 - And/or 
• CT changes: 
- Mucosal changes within ostiomeatal complex and/or sinuses 
 
Table 1 Clinical definition of rhinosinusitis including nasal polyposis10 
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c. Asthma 
Asthma is a chronic inflammatory condition of the lower airways defined by 
largely reversible airflow obstruction, airway hyperresponsiveness and 
mucus hypersecretion, leading to episodic respiratory symptoms; these 
include wheezing, cough, breathlessness and chest tightness. As in AR, Th2 
cells orchestrate the inflammatory response in asthma through the release of 
IL-4, IL-13, IL-5 and IL-911. Asthma is characterized by an inflammatory 
process in which the immune response to allergens is mediated by mast 
cells, CD4+ Th2 cells, eosinophils, dendritic cells, and IgE-secreting B 
cells. Following exposure to proteolytic allergens, the airway epithelium 
condition through cytokines called “alarmins” (TSLP, IL-33, IL-25) 
dendritic cells to drive in the regional lymph nodes naive CD4+ T cells to 
differentiate into Th2 cells. In turn, Th2 cytokines drive cardinal features of 
asthma: IL-4 and IL-13 promote B cells class-switch recombination to IgE 
synthesis; IL-5 induces eosinophil chemotaxis, maturation and survival ; IL-
9 promotes mast cell development; and both IL-9 and IL-13 regulate mucus 
secretion and airway hyperresponsiveness, in asthma and in AR 12. Both 
antigen-driven and nonspecific mechanisms are then able to lead to 
respiratory symptoms such as sneezing, watery rhinorrhea, wheezing and 
chest tightness.  
Asthma and AR are frequently associated. Between 20 and 50% of patients 
with AR have asthma, and 30 to 90% of patients with asthma have 
concomitant AR13;14. 
    
 
 
 
d. COPD 
COPD is defined on lung function testing by poorly reversible airway 
obstruction. The disease is often associating damage to proximal bronchial 
airways (including epithelial mucous metaplasia) and to distal airways and 
airspaces (alveolar destruction, as referred to emphysema). Cigarette 
smoking is by far the most important risk factor in the development of 
COPD, followed by occupation and air pollution15. According to some 
studies, COPD develops in around 25% (15 to 50% according to different 
studies) of heavy smokers16-18. 
More recently, inflammation has also been recognized as a hallmark in 
COPD19. A distinguishing feature of COPD is the local accumulation of 
macrophages, neutrophils and CD8+ T-cells as well as a type 1 (Th1/Tc1) 
cytokine profile11, while Th2-related inflammation with eosinophilic 
infiltration could be seen during some exacerbations20 and in COPD patients 
with hyperresponsiveness improving on corticosteroids. 
Inhaled irritants, such as cigarette smoke, activate epithelial cells and 
macrophages to release multiple cytokines, including IL-8, tumour necrosis 
factor (TNF)-α, IFN-γ or TGF-β, which stimulate fibroblast proliferation, 
resulting in fibrosis in the small airways11;21.  
2. CELLULAR INFILTRATION 
Immune cells infiltrating the airways during such diseases could be divided 
into two distinct groups according to their presume roles; effector leukocytes 
include neutrophils, macrophages, eosinophils, mast cells, basophils and B-
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lymphocytes, whereas regulatory leukocytes are represented by T-
lymphocytes and dendritic cells. 
Neutrophils have the capacity to induce oxidative damage and proteolysis 
through the release of preformed mediators including lysozyme, 
lactoferrine, cathelicidins, defensins, serine proteases (neutrophil elastase, 
proteinase-3 and cathepsin G), as well as matrix metalloproteinase (MMP)-8 
and 95;22. 
Basophils and mast cells can also release preformed inflammatory mediators 
such as histamine, prostaglandin D2, cysteinyl leukotrienes, and neutral 
proteases. These mediators cause sensory neural stimulation and plasma 
exudation from blood vessels, which the patient experiences as itching, 
sneezing, nasal discharge, and congestion as well as lower respiratory 
symptoms23. These cells can also elaborate newly synthesized factors, such 
as leukotrienes and IL-4, contributing notably in allergy to late-phase 
responses to allergen exposure. Eosinophils have a capacity to release 
tissue-toxic granule proteins, leukotrienes and numerous cytokines and are 
predominant infiltrating cells in allergic airway disease (AR and asthma) 
and in CRSwNP24.  Macrophages represent resident phagocytes of lower 
airways, that may be activated by cigarette smoke or pathogens to secrete 
several inflammatory mediators and proteins such as oxygen-derived 
radicals, MMP-2, -9 and -12 (macrophage elastase) as well as cathepsins22.  
Activated mast cells, eosinophils, and basophils infiltrate the airways of 
asthmatics as a result of an excessive Th2 response, while in COPD 
infiltration of neutrophils, macrophages and CD8+/Tc1 lymphocytes is 
observed11. Neutrophilic infiltration in both the airway lumen and tissues 
    
 
 
 
has been shown to correlate with disease severity25. In contrast to asthma, 
eosinophils are not increased in COPD, except in case of asthmatic features 
such as hyperresponsiveness or corticoid reversibility or during some 
exacerbation26.  
The predominant inflammatory cells in AR consist of eosinophils, 
basophils, lymphocytes, macrophages and plasma cells27. Increased 
numbers of T cells have also been reported in CRS, CRSsNP typically 
showing a predominant Th1-cytokine profile and infiltration by neutrophils 
and macrophages28. Conversely, CRSwNP displays a Th2-skewed 
eosinophilic inflammation dominated by eosinophils and mast cells28. Nasal 
polyps include dense concentrations of eosinophils in a stroma that may be 
variably dense or loosely oedematous29. 
 AR CRSsNP CRSwNP COPD Asthma 
Effector 
cells 
Eosinophils 
Basophils 
Neutrophils 
Lymphocytes 
Macrophages 
Eosinophils 
Lymphocytes 
Neutrophils 
Macrophages  
Lymphocytes 
Eosinophils 
Mast cells  
Lymphocytes 
CD4 
profile 
Th2 Th1 Th2 Th1 Th2 
Table 2: Inflammatory and immune cell infiltration in upper and lower airway diseases 
Regulatory cells (Treg cells) are T cells able to suppress effector T cells, 
both from Th1 or Th2, or Th17 phenotype. Treg-mediated suppression 
involves cell-cell contact (e.g. through CTLA4) and/or secretion of 
inhibitory cytokines such as IL-10 or TGF-β. Inhibition of the development 
of allergy by Tregs may occur through several mechanisms, including 
suppression of effector T cells or direct effects on inflammatory cells such 
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as eosinophils, mast cells / basophils, or B cells. Also, they favour isotype 
switching from IgE to IgG430. 
3. IMMUNE DEFENCE MECHANISMS 
The immune defence mechanisms of the nasal mucosa consist of a physical 
and chemical barrier to inhaled microbes, particles and antigens. The 
respiratory epithelium is actively involved in immune responses, innate 
immune recognition relying on a limited number of germline-encoded 
pathogen related receptors (PRRs) such as Toll-like receptors (TLR) and 
nucleotide binding oligomerization domains31. These receptors recognize a 
variety of conserved molecules, commonly present on viruses and bacteria 
named pathogen associated molecular patterns (PAMPs), including 
lipopolysaccharide (LPS), lipoteichoic acid (LTA), mannans, glycans or 
bacterial/viral nucleic acids (double or single-stranded DNA and RNA) and 
which signal downstream to intracellular cascades that result in the gene 
transcription of antimicrobial and inflammatory cytokines32. Other functions 
of PRRs include opsonization, phagocytosis, and induction of apoptosis32. 
Signals provided by TLR are essential to induce dendritic cell maturation 
that subsequently allows priming of naive T cells during primary immune 
responses to a newly recognised antigen33. Through induction of 
costimulatory molecules and cytokines, the innate immune system also 
primes adaptive immune responses34. PRRs are expressed on most cells of 
the immune system such as macrophages, dendritic cells, B-cells as well as 
on respiratory epithelial cells, but may also be resident in intracellular 
compartments or secreted as soluble molecules into the bloodstream and 
tissue fluids 5. 
    
 
 
 
a. The respiratory epithelium 
The airway epithelium constitutes the interface between the host and the 
external environment and is thereby constantly exposed to potentially 
infectious agents such as bacteria, viruses, fungi and parasites, as well as 
potentially harmful soluble molecules from the environment. It produces a 
large array of molecules and mediators (Table 3 and 4), whereas it could 
also play a suppressive role on immune responses to harmless antigens. 
Thus, epithelial cells, beyond their role as a physical barrier, are active 
players during innate and adaptive immunity. 
Sinonasal and bronchial mucosa are similar histologically, both being 
characterized by a ciliated pseudostratified columnar epithelium resting on a 
basement membrane and covered with a bilayer of surface fluid, with a 
superficial gel or mucous layer and a layer of periciliary fluid interposed 
between the mucous layer and the epithelium. In the normal maxillary sinus, 
more than 90% of the mucosal surface area is covered with cilia35. Further 
down to proximal bronchi, distal (membranous) bronchioles are lined by an 
columnar epithelium becoming more cuboidal36. Concomitantly to 
disappearance of cartilage and submucosal glands, distal (or ‘peripheral’, 
‘small’) airways are characterized by the emergence of Clara secretory 
cells36. At least eight morphologically distinct epithelial cell types have been 
observed in the bronchial airways, although based on ultrastructural, 
functional and biochemical criteria these may be classified into three main 
categories: basal, ciliated and secretory37. In large airways (20 to 25 
branches in humans), the most represented cell types are ciliated, secretory, 
basal cells, and undifferentiated columnar cells. In distal airways (26 to 223 
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branches), similar cell types are observed, with increased proportion of 
ciliated cells and a shift of secretory to Clara cells. After 223 branches, the 
airway epithelium (in respiratory bronchioles) merges with the alveolar 
epithelium, with mostly type I and type II cells36. 
Mucus-secreting goblet cells are present all along the respiratory tract. In 
the upper airway mucosa, their density varies from one sinus to another, 
with a maximal density of 10.000 cells/mm² in the maxillary sinus8.  In the 
bronchi, goblet cells represent 5 to 15% of the columnar cell population, 
their proportion decreasing in more distal airways. 
The airway epithelium is a source of numerous mediators in allergic 
inflammation, but might also play a key primary role during sensitization. 
Functional dysregulation of the so-called epithelial-mesenchymal trophic 
unit has been suggested in asthma39, favouring Th2-type allergic 
inflammation through abnormal repair processes and production of 
proinflammatory factors, but it remains controversial whether this occurs 
also in the nose.  
 
 
 
 
 
 
 
    
 
 
 
Defence mechanisms of the respiratory tract 
 Humoral Cellular 
Mechanical Mucociliary clearance Ciliated epithelium 
Adaptive Immunity 
(Specific) Immunoglobulins 
Lymphocytes (T and B 
cells) 
Innate Immunity 
 (Aspecific) 
Glycoproteins 
• Mucins  
• Lysozyme 
• Lactoferrine 
• pIgR 
• Surfactant proteins  
• Clara protein 
• sPLA2 
Anti-inflammatory and 
 antibiotics  
• Neutral endopeptidase 
• Annexins 
• Defencins 
• Cathelicidins 
Anti-proteases 
• SLPI 
• Alpha-1-antitrypsin 
Eicosanoids  
• Leucotriene B4 
• Prostaglandins 
• Lipoxin 
Cytokines 
Granulocytes 
Macrophages 
Table 3: Defence mechanisms of the respiratory tract (Adapted from Aubier et al. Traité de 
Pneumologie 2ème edition) pIgR, polymeric immunoglobulin receptor; sPLA2, secretory 
phospholipase A2; SLPI, secretory leukocyte proteinase inhibitor  
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b. Remodelling 
Remodelling is defined as a process leading to transient or permanent 
changes in tissue architecture, which involves changes in tissue structures 
(basement membrane and interstitial stroma) that result from insults that are 
not adequately balanced by appropriate repair mechanisms. There is now 
very strong evidence that structural components are playing a driving role in 
inflammatory airway disease, along with immunological mechanisms per 
se. Functional changes in the function of epithelium and mesenchymal 
tissues, referred morphologically to as “remodelling”, may lead to vicious 
circles of impaired frontline defence mechanisms (mucociliary clearance, 
epithelial proteins including defensins, secretory-IgA) and exaggerated 
immune cell recruitment. Recent studies show that impairment of innate 
protective mechanisms of the airway epithelium, such as production of 
TGF-α40 and IFN-β41 is part of abnormal epithelial repair responses to viral 
infections in asthma. Most of this evidence of such implication of structural 
tissues –including epithelial cells and (myo)fibroblasts– has thus been 
obtained in asthma, and whether this extends to rhinitis remains uncertain42. 
Some studies suggest similar mechanisms in allergic rhinitis in terms of 
epithelial shedding43 and myofibroblast activation44, but this was not 
confirmed by others45. Increased vascular permeability46 and angiogenesis47 
has been observed in allergic rhinitis. Also there is evidence of persistent 
epithelial activation in perennial allergic rhinitis, such as ICAM-1 
expression48. If it appears that tissue changes occur in the upper airways to a 
lower extent than in lower airways, it is also clear that remodelling 
processes are engaged in allergic rhinitis, including increased expression of 
    
 
 
 
TGF-β49 and VEGF50, even if final consequences on tissue structure might 
not be discerned as easily as in lower airways in asthma. Other factors that 
could contribute to chronicity of airway inflammation include superantigens 
from commensal Staphylococcus aureus51 and exposure to a range of 
environmental stimuli such as viruses, tobacco smoke and ambient air 
pollution. 
A typical change observed in many chronic airway disorders consists of 
hyperplasia and metaplasia in mucus-secreting cells, particularly observed 
in the bronchi52. During inflammatory responses in the airways, resolution 
occurs through apoptosis of inflammatory leukocytes that have been 
recruited and activated locally, while repair of collateral damage to 
neighbouring tissue – in particular to the surface epithelium – includes 
regeneration from epithelial basal cells that can differentiate into a 
specialized cell type. These basal cells serve as progenitor niches within 
proximal airways - from the nose to large bronchi52, whereas in distal 
airways studies indicate that Clara cell (and Clara cell variants) or basal 
cells could play this role53.  
c. Mucociliary clearance 
Mucociliary clearance is considered the first line of defence against bacteria 
deposited in the airways, acting as a physical barrier54. The epithelial lining 
fluid covering the upper and lower airways is a twofold layer consisting of a 
superficial gel or mucous layer and an underlying, watery fluid that 
surrounds the cilia on the apical surface of the ciliated cells, called airway 
surface liquid (ASL)55. The mucus is produced by surface goblet cells and 
by submucosal glands. The gel-like properties of the mucus depend 
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primarily on their content of high molecular weight glycoproteins known as 
mucins, which behave as a tangled three-dimensional polymer network. 
These macromolecules immobilize inhaled microbes and particles into the 
mucus and/or destroy them54. Surrounding macrophages can engulf and 
destroy bacteria but also release cytokines that will attract neutrophils and 
other cells56. Effective mucociliary clearance depends on the viscoelastic 
properties of mucus and requires coordinated ciliary activity. This basic 
physiological properties of mucus and ciliary function are impaired in most 
chronic disorders such as chronic sinusitis57 and COPD58, at least in part as 
a result of secondary ciliary dyskinesia. 
In addition to physical properties of mucus, ASL contains multiple proteins 
and peptides that provide an antimicrobial shield; these include lysozyme, 
lactoferrin, secretory leukocyte proteinase inhibitor (SLPI), elafin, secretory 
phospholipase A2 (sPLA2), anionic peptides, cathelicidin (LL-37) and β-
defensins56. These anti-microbial factors have many roles during innate 
immune responses, including broad spectrum antimicrobial activity, the 
ability to act as chemokines as well as to induce chemokine production 
leading to recruitment of leukocytes to the site of infection, the promotion of 
epithelial wound repair and the ability to modulate adaptive immunity59. 
Although several antimicrobial peptides are constitutively expressed, their 
expression and secretion can be triggered through several pathways, 
including proinflammatory cytokines as well as bacteria or PAMPs60. Some 
of these factors, especially lysozyme, lactoferrin and SLPI, interact to 
enhance their activity61. 
    
 
 
 
d. Defence (glyco)proteins 
i. Mucins 
The major protein component in the mucus is a family of highly 
glycosylated, viscoelastic, disulfide-bonded glycoproteins named gel-
forming mucins. Mucins are characterized by a large molecular weight (2–
20 x 105Da), high carbohydrate content reflecting a large number of O-
glycans, and numerous tandem repeats in the protein backbone62.  They are 
secreted in vesicles derived from the Golgi apparatus, stored in the 
cytoplasm of goblet cells and released by exocytosis at their apical surface 
in response to mucin secretagogues38. Of the currently known 20 mucin 
genes that encode protein backbone of mucins, 16 have been identified in 
the airways38. The epithelial mucins are extremely hydrophobic and are 
associated with various macromolecules, the quality and quantity of which 
may also affect the physicochemical properties of the mucus. 
A wide variety of stimuli, including allergens, bacteria, mechanical injury, 
cigarette smoke and cytokines can induce mucus secretion via epidermal 
growth factor receptor (EGFR) expression and activation, causing goblet-
cell metaplasia from Clara cells by a process referred to as cell 
transdifferentiation63. Since airway inflammation is usually accompanied by 
mucus hypersecretion, any condition causing inflammation is likely to 
stimulate mucin release in the airways, either directly or indirectly64. 
Accordingly, many chronic inflammatory diseases of the lower respiratory 
tract are associated with mucus hypersecretion, which contributes to airway 
obstruction in patients with asthma, COPD, or cystic fibrosis62. Mucus 
hypersecretion is also associated with AR65 and CRS66, either with or 
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without nasal polyps, characterized by increased numbers of goblet cells 
within the surface epithelium63 and/or increased numbers of submucosal 
glands67.  
ii. Lysozyme and lactoferrin 
Lysozyme and lactoferrin are the most abundant antimicrobial factors in 
nasal secretions68. Lysozyme is a 14kDa polypeptide contained within both 
phagocytic and secretory granules of neutrophils, whereas it is also 
produced by monocytes, macrophages, and epithelial cells5. Lysozyme can 
destruct the cell wall from bacteria by cleaving glycosidic bonds of N-
acetylmuramic acid, and induces cell lysis. It is also toxic for various fungi 
but has no specific impact on antiviral defence. Increased production of 
lysozyme has been observed in the nasal mucosa of patients with chronic 
rhinosinusitis69 and in BAL fluid of patients with COPD70. Conversely, a 
significant decrease in lysozyme levels was reported in patients with allergic 
rhinitis and CRS compared to patients with allergic rhinitis alone or 
controls71. Lysozyme C precursor has also been shown to be down-regulated 
in CRS patients when compared to normal subjects72. 
Lactoferrin, as lysozyme, is a major component of secretory granules of 
neutrophils and is found in high concentration in several biological fluids. 
Its structure is very similar to the serum iron transporter transferrine. 
Although  chelation of iron represents its key biological function, this 
80kDa glycoprotein is also very prone to bind other macromolecules such as 
IgA, secretory component and lysozyme73. Almost all microorganisms need 
iron for growth, therefore by sequestering iron and making it inaccessible to 
invading organisms lactoferrin exerts a bacteriostatic effect on Gram 
    
 
 
 
positive and Gram negative bacteria and yeasts74;75. Other activities include 
anti-inflammatory activity and the regulation of cell cycle and 
differentiation76. Lactoferrin secretion has been shown to be 2-fold higher in 
bronchial than in nasal mucosa77, and enhanced concentrations have been 
found in BAL fluid from patients with COPD70 or asthma78. In contrast, 
recent studies reported a reduction in lactoferrin expression in the nasal 
mucosa of CRS patients, at both mRNA and protein levels79. 
iii. pIgR and IgA 
S-IgA, the most abundant Ig isotype in mucosal secretions, is involved in 
both innate and adaptive immunity as it can be produced either with or 
without defined antigen specificity. High affinity IgA antibodies play a 
critical role in protective adaptive immunity, while ‘low affinity’ IgA 
antibodies (sometimes referred as to ‘natural antibodies’) represent a high 
capacity innate, frontline defence system80. B cells in upper airways are 
initially stimulated in organized mucosa-associated lymphoid tissue, known 
as nasal associated lymphoid tissue (NALT), which includes the tonsils and 
adenoid. The existence of bronchial associated lymphoid tissue (BALT) 
remains elusive in homeostasis but does emerge in the lower airways from 
pathology, particularly in COPD81 From these inductive sites, memory B 
cells migrate to secretory effector sites where they differentiate into terminal 
Ig-producing plasma cells82. Monomeric IgA (mIgA) is constituted by two 
non-specific light chains covalently associated with two specific heavy 
chains and has a molecular weight of 160kDa2. IgA is synthetized by 
mucosal B cells in the mucosal lamina propria as dimers, with two IgA 
monomers joined by the joining (J) chain in a “tail-to-tail” conformation, 
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whereas larger polymers (trimers, tetramers, and even pentamers) can also 
be found in low amounts.  
Polymeric IgA must be translocated from the subepithelial area into mucosal 
secretions, across the epithelium. A specific receptor for polymeric Igs called 
polymeric Ig receptor (pIgR), expressed at the basolateral pole of epithelial cells, 
is assuming this active transport. IgA is transcytosed by the pIgR up to the apical 
surface where a proteolytic cleavage releases the main part of the pIgR 
extracellular domain known as secretory component (SC), which helps 
protecting the molecule from proteolysis2. The pIgR is expressed in bronchial 
and nasal mucosae, as well as in the digestive and urogenital tracts, and S-IgA in 
respiratory secretions may exert protective anti-microbial activities by 
scavenging pathogens and antigens. As pIgR transcellular routing also occurs 
without IgA, free SC is released which is also able to contribute to pathogen 
scavenging. pIgR expression and function is upregulated through multiple 
signaling pathways initiated by PAMPs and pro-inflammatory cytokines such as 
IFN-γ, IL-4, TNF-α, and IL-14;83. However, reduced pIgR expression has been 
observed in the airways of severe COPD patients, and this impairment correlated 
with airflow obstruction and with neutrophil infiltration of submucosal glands2. 
A significant increase of IgA has been shown in tissue homogenates, but not in 
serum, of CRSwNP patients, when compared to CSRsNP patients and controls, 
suggesting a local production84. 
iv. Surfactant proteins 
Surfactant is a lipoprotein complex composed of 90% phospholipids and 10% 
proteins, designated as SP-A, SP-B, SP-C, and SP-D85;86. SP-A and SP-D are 
hydrophilic glycoproteins, members of the collectin family, which exhibit 
    
 
 
 
antimicrobial and interact with a variety of bacterial, viral and fungal 
pathogens86. In addition, SP-A and SP-D can interact with dendritic cells and 
modulate subsequent T-cell responses, optimize leukocyte function and 
chemotaxis, and affect subsequent cytokine/chemokine profiles and activate 
complement87. Conversely, SP-B and SP-C are hydrophobic proteins which 
increase the rate which surfactants spread over the surface85. Surfactant proteins 
have long been considered lung-specific but recent studies showed that SP-A88, 
SP-B89 and SP-D86 - but not SP-C - are also expressed in the nasal mucosa.  
v. Clara cell protein 
Clara cell protein (CC10, also referred to as CC16 or uteroglobin) is a 15.8-kDa 
homodimeric protein secreted in large amount in distal airways (bronchioles) 
where Clara cells are localized90, whereas gene expression can be detected along 
the tracheobronchial tree. CC10 is a steroid-inducible protein with 
immunomodulatory (mainly through inhibition of phospholipase A2) and 
antiproteinase properties91 which helps to protect the lung during local 
inflammatory responses92. The secretion of CC10 is upregulated by cytokines 
such as TNF-α93 or IFN-γ94. The serum concentrations of CC10 are decreased in 
subjects with asthma91, whereas results in COPD have been more contradictory. 
Decrease in CC10 has been reported in the serum from COPD in one study (78), 
but not in another91. Decreased CC10 content has also been observed within 
proximal and distal lower airways from severe COPD patients and cystic fibrosis 
patients95 as well as in smokers without COPD2. In the BAL fluid of asthmatic 
patients, CC10 has been shown to be 10-fold lower than in healthy volunteers96. 
There is increasing evidence that acute exposures to respiratory irritants could 
cause transient increases in serum CC10 levels90;97. Whereas Clara cells in 
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humans are restricted to terminal bronchioles, CC10 protein has also been found 
in nasal secretions98 and could be involved in the pathogenesis of upper airways 
diseases. Recently, it was shown that CC10 production is reduced in CRS with or 
without NP97 as well as in allergic rhinitis99.  
vi. sPLA2 
Phospholipase A2 (PLA2) enzymes are a family of esterases which play a 
major role in the generation of two inflammatory lipid mediators: 
eicosanoids and platelet-activating factor (PAF). Among them, ten secretory 
PLA2 (sPLA2) have been identified and described as structurally related, 
disulfide-rich, low-molecular mass enzymes with strict Ca2+ dependence100. 
sPLA2 are usually expressed and released by granulocytes (mast cells, 
basophils, eosinophils) and Th2 cells101. They are involved in hydrolysis of 
outer cell membrane phospholipids and in antibacterial defence through 
maturation, recruitment, and activation of inflammatory cells100. sPLA2s  
also induce degranulation and production of cytokines and chemokines from 
inflammatory cells, such as monocytes/macrophages and eosinophils101. 
sPLA2s are released in the airways of patients with allergic asthma and 
rhinitis101, and Lindbom et al. found a large number of PLA2 types in nasal 
and paranasal fluids and mucosal tissues from control and allergic rhinitis 
patients102. In addition, Touqui et al. showed that sPLA2 activity increases 
in nasal lavage fluid from allergic patients after allergen provocation103. 
Recently, Liu et al. have showed that the expression of some members of 
group II subfamily of sPLA2s (sPLA2-IIA, IID, IIE) is upregulated in 
CRSsNP100. When comparing polyp tissue and non-polyp sinusal tissue, 
they found that polyps displayed significantly lower sPLA2-IIA mRNA and 
    
 
 
 
higher expression of sPLA2-IIE mRNA, than specimens from CRSsNP 
patients100. Similarly, in lower airways, bronchial instillation of sPLA2 can 
induce bronchoconstriction and tissue damage104, and elevated levels of 
sPLA2 are found in BAL105 and sputum106 from asthmatics. 
e. Anti-inflammatory and antimicrobial proteins/peptides 
i. Neutral endopeptidase 
Neutral endopeptidase (NEP) is a highly selective glycoprotein, regulating 
the activity of neuropeptides released in the respiratory mucosa107. In the 
airways, NEP represents the major enzyme which reduces cellular responses 
to neuropeptides. NEP secretion is regulated by the glandular, cholinergic 
system108. Functions of respiratory epithelia and inflammatory cells are 
influenced, at least in part, by biologically active agents released from both 
sensory and efferent autonomic nerves, and neurogenic inflammation has 
been shown to be different in upper and lower airways. The nasal mucosa is 
especially densely innervated by sensory nerves which, when stimulated, 
activate protective reflexes such as sneezing, rhinorrhea and nasal 
congestion, in order to assure first line defence against pathogens and 
particles109. On the other hand, lower airway neurogenic inflammation is 
characterized by plasma protein extravasation, airway smooth muscle 
contraction and increased secretion of mucus110. Reduced peptidase 
activities in serum or BAL fluid are found in healthy smokers when 
compared to non-smokers111, suggesting that smoking may affect per se 
NEP-mediated control of neurogenic inflammatory responses. 
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ii. Annexins 
Annexin A1, also known as lipocortin-1 or calpactin II, is a calcium-
dependent glucocorticoid-inducible protein. Annexin A1 has been 
implicated in various cellular processes such as neutrophil migration, 
apoptosis, intracellular signal transduction, membrane-cytoskeletal linkage, 
regulation of cell growth and differentiation112-114.  Annexin-1 also inhibits 
the activity of cytosolic PLA2 (cPLA2). Given that cPLA2 plays a key role 
in the release of arachidonic acid for the production of eicosanoid 
inflammatory mediators, the inhibition of this enzyme by annexin-1 is 
thought to contribute to its anti-inflammatory activity112. Annexin A1  was 
found to be constitutively expressed in normal nasal mucosa and is detected 
in bronchoalveolar lavage fluid114. 
Enhanced annexin A1 mRNA and protein expression was reported during 
chronic inflammation of the nasal mucosa114. In contrast, Lindahl et al. 
showed a significant reduction of lipocortin-1 in subjects with rhinitis, when 
compared to healthy subjects96, as well as in nasal epithelial cells from CF 
patients115. It has been suggested that expression of annexin A1 in the nasal 
epithelium could be related to the cellular differentiation status rather than 
chronic inflammation113. In a mouse asthma model, allergen-induced 
oxidative stress results in proteolysis of annexin A1 and subsequently up-
regulation of cPLA2 activity and LT production116. In humans, higher levels 
of annexin A1 are present in the BAL fluid of asthmatic patients and 
smokers, when compared with healthy volunteers117.  
    
 
 
 
iii. Defensins 
Defensins are endogenous small highly cationic peptides found at epithelial 
surfaces, that can be divided into two main subgroups, namely α- and β-
defensins which differ in their distribution and connection of six cysteine 
residues118. While α-defensins are produced by neutrophils and intestinal 
Paneth cells, β-defensins are mainly expressed by epithelial cells119. Both 
subclasses possess antimicrobial activity against Gram-positive and Gram-
negative bacteria, enveloped viruses, mycobacteria and fungi5;120. This 
activity relates to their ability to disrupt the membranes of a wide range of 
organisms, causing permeability changes and cell death120. Defensins are 
chemotactic for T cells and therefore may be capable of activating T cell-
dependent immune responses121. Beta-defensin genes are induced in the 
airways by bacteria and TLR agonists122. 
Recent studies reported overproduction of defensins in CRS patients either 
with123 or without124 nasal polyps, when compared to healthy volunteers, 
while low concentrations of β-defensins-4 have been observed in patients 
with AR125.  In the lower airways, elevated defensins levels were also 
observed in sputum from patients with CF126 while reduced defensin activity 
due to elevated salt concentration has been implicated in the pathogenesis of 
CF lung disease127. Upregulation of defensins 1 and 2 was also documented 
in BAL fluid of smokers with COPD compared to asymptomatic 
smokers128, and recent studies reported associations of a polymorphism in 
the gene encoding human β-defensin-1 with asthma129 and with COPD130. 
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iv. Cathelicidins 
Cathelicidins, like defensins, are produced by various cell types, including 
neutrophils,  macrophages, dendritic cells, T cells and epithelial cells131. The 
only cathelicidin expressed in humans, LL-37, has been shown to have a 
broad-spectrum activity similar to that of defensins, against both Gram-
positive and Gram-negative bacteria, as well as Candida albicans, and is 
able to neutralize LPS132. It mediates a wide range of biological responses: 
direct killing of microorganisms, chemoattraction of leukocytes, 
chemokine/cytokine release, lung epithelial cell proliferation, neutralisation 
of endotoxins such as LPS, stimulation of angiogenesis, as well as 
promotion of wound closure of the airway epithelium133.  
Recent studies showed that LL-37 mRNA was increased in nasal polyps134 
and in CRS patients135 when compared to normal nasal mucosa. Similarly, 
increased concentration of LL-37 was detected in the sputum of COPD 
patients, whereas reduced levels were observed in asthma136.  
v. Anti-proteinases  
SLPI is a 12-kD non-glycosylated tissue-specific inhibitor of serine 
proteases, produced by epithelial cells at mucosal surfaces. By inhibiting 
neutrophil elastase, cathepsin G and mast-cell chymase, it prevents damage 
to the ciliated epithelium during bacterial infections137. Recent studies 
indicate that SLPI also exhibits anti-inflammatory properties138 and provides 
a weak but broad-spectrum antimicrobial activity, killing micro-organisms 
and limiting viral spreading139. Atopic patients have a lower concentration 
of SLPI in nasal secretions than healthy subjects, independently of antigen 
exposure137, whereas a rise in SLPI is observed following antigen 
    
 
 
 
challenge137. No data are reported regarding SLPI in CRS, while in lower 
airways a reduction of SLPI has been shown in COPD140. Its level in sputum 
of COPD patients varies inversely with infection141 and the concentration of 
neutrophil elastase142, and its activity is affected by oxidative stress143. 
Hollander et al. did not find significant differences in BAL fluid levels of 
SLPI between COPD and asthma patients144. 
vi. Lipid mediators (eicosanoids) 
Arachidonic acid is the initial substrate for lipid-derived mediators, also 
called eicosanoids, representing plasma membrane phospholipid-derived 
polyunsaturated fatty acids. These mediators, which include leukotrienes 
(LTs), prostaglandins (PG) and lipoxins (LXs) are generated subsequently 
to the hydrolytic action of PLA2 on cellular phospholipids to release 
arachidonic acid, via the cyclooxygenase or lipoxygenase pathways145. 
Eicosanoids are produced by airway epithelial cells under baseline 
conditions or in response to various stimuli, actively perpetuating chronic 
inflammation145. Eicosanoids play an important role in the pathophysiology 
of airway diseases associated with inflammation, platelet aggregation and 
vasoconstriction/relaxation dysbalance. 
Cysteinyl leukotrienes (CysLTs) are a family of pro-inflammatory lipid 
mediators synthesized by a variety of cells, including mast cells, 
eosinophils, basophils, and macrophages and to a lesser extent T cells and 
endothelial cells146;147. CysLTs have potent effects on vasodilation and 
leakage, bronchoconstriction, mucus secretion, collagen synthesis, 
leukocyte trafficking, epithelial proliferation, P-selectin increase, as well as 
production, adhesion, migration and survival of eosinophils147;148. In the 
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lung, CysLTs also augment growth factor-induced airway smooth muscle 
mitogenesis149, in addition to their direct bronchoconstrictive capacity. 
CysLT are increased in nasal secretions from patients with allergic rhinitis, 
following local antigen challenge and natural (seasonal) allergen 
exposure148, and correlate with the intensity of the allergen provocation and 
the clinical response150. Increased concentrations of CysLT have also been 
observed in nasal secretions, nasal mucosa or polyp tissue from patients 
with CRSwNP151 and their concentration correlated with disease severity152 
and eosinophilic inflammation153. Also CysLT levels are increased in the 
urine154, BAL fluid155 and sputum156;157 of asthmatic patients; increased 
sputum levels correlating with eosinophils158 and disease severity156. Such 
increase has also been reported in sputum of COPD patients157.   
Prostaglandins. The capacity of the epithelium for CysLT synthesis is 
inversely related to its ability to produce PGE2, which is the predominant 
eicosanoid product of the airway epithelium149. PGE2 is catalyzed by 
cyclooxygenase (COX) 2 in response to stimulation by many inflammatory 
cytokines such as platelet-derived growth factor (PDGF), IL-1β and TNF-
α159;160. PGE2 is produced within the nasal and bronchial mucosa, but it 
remains unclear whether it can play a deleterious or a beneficial role in 
pathology. Several studies showed that PGE2 has a protective and anti-
inflammatory role in asthma, with an inhibitory effects on eosinophils 
trafficking, release of inflammatory mediators, and allergen-induced airway 
responses161. Moreover, numerous studies have shown the ability of PGE2 
to induce bronchodilation162, whereas other prostanoids such as TXA2, 
PGD2 and PGF2a mediate varying degrees of bronchoconstriction163. PGE2 
    
 
 
 
has also important roles in mitogenesis inhibition, collagen synthesis and 
mesenchymal cell chemotaxis. On the other hand, recent studies 
demonstrated PGE2 as a pro-inflammatory mediator that responds to 
inflammatory cytokine stimulation159, enhances mucin gene expression164 
and eosinophil survival165, and regulates Th17 development166. 
PGE2 also modulates the immune response by regulating macrophages, T 
and B lymphocytes leading to pro- and anti-inflammatory effects167. The 
existence of four PGE2 receptors, each with distinct signalling pathways, 
provides a plausible explanation for the apparent contradictory actions of 
this lipid mediator168. Several studies revealed increased expression of 
PGE2 in patients with asthma165 and COPD159;160 and PGE2 concentration 
were directly correlated with eosinophils in asthma165 and with airflow 
limitation in COPD159. However, Kostikas suggested that the elevation of 
prostaglandin E2 in patients with asthma could mainly be attributed to 
smoking169. Indeed, deficient PGE2 production under proinflammatory 
conditions has been demonstrated in asthmatic airways170.  
On the other hand, PGE2 is significantly decreased in peripheral blood cells 
and in nasal polyp tissue as compared with normal nasal mucosa152 and the 
PGE2 concentration could be inversely correlated to eosinophilic 
inflammation152 and the radiological severity of sinusitis171. In patients with 
allergic rhinitis, lower local levels of PGE2 were reported, when compared 
with normal mucosa172.  
The reason for the apparent discrepancy of PGE2 levels between allergic 
rhinitis and asthma might relate to several factors among which are timing 
of sampling according to the kinetics of immune responses to antigen 
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exposure and methodological issues. Also, differences in receptor ligation 
and signalling in target cells may account for different effect of PGE2. 
Thus, PGE2 appears to regulate inflammation in a complex way, with subtle 
differences between patients according to primary pathology, as well as to 
airway level and smoking status. 
Lipoxins. LXs are also generated by the metabolism of arachidonic acid, via 
enzymatic conversion by 12/15-lipoxygenase152. These molecules are the 
originally described endogenous lipid mediators of the resolution phase of 
inflammation. LX A4 is a short-acting, naturally occurring eicosanoid with 
potent anti-inflammatory actions, which can provide suppressive signals for 
leukocyte trafficking152. LXA4 is generated in asthmatic responses173 and 
inhibits airway hyperreactivity and lower-airway inflammation174. Several 
studies showed decreased levels of LXs in the airways of severe asthmatic 
patients157, while no data are reported in COPD. In the upper airways, nasal 
polyp tissue displays high LX production175 and enhanced LX levels were 
shown in CRS, either with and without nasal polyps, compared with control 
subjects152.  
 
 
 
 
 
    
 
 
 
 
AR CRSsNP CRSwNP COPD Asthma Refs 
Glycoproteins 
Mucins Increased Increased Increased Increased Increased 62;63;65;66 
Lysozyme Unknown Contradictory Unknown Increased Increased 69-72 
Lactoferrine Unknown Decreased Unknown Increased Increased 70;78;176 
CC10 Decreased Decreased Decreased Decreased Decreased 2;96;177 
SPLA2 Increased Increased Contradictory Unknown Increased 100;105;106 
Anti-inflammatory and antimicrobial peptides 
Annexins Contradictory Contradictory Contradictory Unknown Contradictory 
120;123;125;1
28
 
Defensins Decreased Increased Increased Increased Unknown 
120;123;125;1
28
 
Cathelicidins Unknown Increased Increased Increased Decreased 134-136 
Anti-proteinases 
SLPI Decreased Unknown Unknown Decreased Decreased 
22;137;140;14
4
 
Eicosanoids 
LT B4 Increased Increased Increased Increased Increased 
148;151;155-
157
 
PGs Decreased Decreased Decreased Increased/ Decreased Increased 
152;159;160;1
65;170-172
 
LXs Unknown Increased Increased Increased Decreased 152;157;175 
Table 4: Inflammatory mediators in upper and lower airway diseases 
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f. Cytokines 
Cytokines play a critical role in orchestrating the immune and inflammatory 
responses, as well as structural changes of the respiratory tract, by 
recruiting, activating and promoting the survival of leukocytes11 and by 
acting on structural cells. According to a large body of literature in mice and 
in humans, T-cell derived cytokines are now frequently used as 
‘biomarkers’ to phenotype the immunopathological profile of immune-
mediated diseases, including in the respiratory tract (Table 5). Besides the 
T-lymphokines, other cytokines play important roles in regulating immune 
responses to pathogens or to intrinsic factors underlying the disease. 
T-cell-derived cytokines. Based on their pattern of cytokine secretion, 
CD4+ lymphocytes can be functionally divided into a Th1 or Th2 
phenotype. Cytokines generally produced by one T cell subset inhibit the 
development of the other subset, leading to polarization of the immune 
system. Th1 cells, through the release of cytokines such as IFN-γ and TNF-
α, activate macrophages and cytotoxic T lymphocytes (CD8+ CTL). In 
contrast, Th2 are involved in atopic diseases by secreting notably IL-4, IL-5, 
IL-9 and IL-13. These cytokines trigger humoral immunity (IgG and IgE 
secretion) and orchestrate the recruitment, proliferation and activation of 
basophils, mast cells and eosinophils29. Thus the presence of eosinophils in 
the airways is strongly linked to that of Th2 cells178, which produce IL-5 as 
principal pro-eosinophilic cytokine. In the bronchi, asthma is associated 
with Th2 cell cytokine responses179, while COPD is considered as a Th1-
biased disease. A similar dichotomy between Th1-Th2 polarization is 
described in the sinonasal mucosa, with IFN-γ and TGF-β being 
    
 
 
 
predominant in CRSsNP and IL-5 characterizing CRSwNP180. In AR, T-cell 
activation is also indicating a Th2 profile. However, in humans, allergen-
stimulated T cells from atopics are also able to produce IFN-γ at baseline, 
and the Th1/Th2 ratio may increase following allergen stimulation181. 
Impaired production of both IL-10 and IL-12 has been observed in blood 
monocytes from atopic patients with asthma182, suggesting a deficient 
capacity of these antigen presenting cells to drive Treg and Th1 immune 
responses to allergens in these subjects genetically susceptible to develop 
atopic diseases. 
A third subset of effector T helper cells, called Th17 cells, are characterized 
by the production of various cytokines, including IL-17A, also called IL-17, 
IL-17F, IL-6, TNF-α, IL-21 and IL-22. Many of the inflammatory effects of 
Th17 cells are attributed to the expression of IL-17. IL-17 acts on airway 
epithelial cells, lung fibroblasts and other types of inflammatory cells to 
trigger the production of pro-inflammatory cytokines, chemokines and 
MMP, promotes the recruitments of neutrophil and macrophage, and leads 
to tissue inflammation183. 
An increase of IL-17 has been shown in serum183;184 and bronchi185 of 
asthmatic patients, and in the bronchi186 of COPD patients, as well as in 
allergic rhinitis187 and CRSwNP185.  
The helper T cell subsets have grown in numbers, with Tregs and Th17 
enriching the Th1/Th2 families. More recently, a specific T cell subset 
secreting IL-9 (Th9) has been reported188.  These Th9 cells are related to 
Th2 cells, but they have lower expression of other Th2 cytokines189 
Interestingly, TGF-β reprograms Th2 cells to lose their characteristic profile 
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and switch to IL-9 secretion or, in combination with IL-4, drives the 
differentiation of Th9 cells directly189. An increase in the expression of IL-9 
mRNA has been shown in COPD patients190, and IL-9 expression is 
increased in asthma191. It is also increased in CF, suggesting that IL-9 is a 
key mediator of mucus hypersecretion in various chronic airway diseases. In 
the nasal mucosa, IL-9 is upregulated during the pollen season and 
correlates with tissue eosinophils in patients with allergic rhinitis192. 
Regulatory T cells (Tregs) are T cells that are thought to suppress 
excessive (allergic) or misguided (autoreactive) immune responses that can 
be harmful to the host, in order to maintain peripheral tolerance. Different 
CD4+ Treg subsets have been identified, which include adaptive Treg cells 
and naturally occurring Treg cells characterized by the CD25 forkhead box 
P3 (FOXP3) phenotype. 
 The Treg cell response is characterized by abolished allergen-induced 
specific T-cell proliferation (as referred to as “anergy”) and suppressed Th1- 
and Th2-type cytokine secretion. The increased levels of IL-10 and TGF-β 
that are produced by Tregs, potently suppress IgE production, while 
simultaneously increasing production of non-inflammatory isotypes IgG4 
and IgA, respectively. In addition, Tregs directly or indirectly suppress 
effector cells of allergic inflammation such as mast cells, basophils, and 
eosinophils193. A relative defect of peripheral and local CD4+CD25+ Treg 
function has been observed in allergy194 and in allergic asthmatics195;196, 
allowing Th2 cells to expand. An increased number of Treg cells in the 
BAL of COPD patients has been observed, but also in smokers lungs, so 
this increase could be associated to long-term cigarette smoke exposure197. 
    
 
 
 
Van Bruaene et al. showed a lower level of FOXP3 in CRSwNP, signing a 
decrease of Tregs, while no significative difference was noted in 
CRSsNP198. 
TSLP Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine, 
initially identified in thymic stromal cells, but predominantly produced by 
epithelial cells and activated mast cells199. Through a potent activation of 
myeloid dendritic cells, TSLP can promote naïve CD4+ T cells to 
differentiate into Th2 cells producing IL-4, IL-5, and IL-13, while inhibiting 
the production of IL-10 and IFN-γ200. Increased epithelial TSLP expression 
can be elicited by exposure to viral or bacterial pathogens and/or by ligating 
TLRs201, and further increases upon Th2 stimulation202. Overproduction of 
TSLP has been described in the epithelial layer of nasal mucosa of patients 
with AR200, and Schleimer et al. found elevated TSLP mRNA levels in 
CRSwNP but without changes in TSLP protein202. High amounts of TSLP 
have also been found in the airways of asthmatic subjects203 and ‘asthmatic 
mice’204, in line with the Th2 hypothesis. However, Ying et al. recently 
showed similar increases of TSLP in COPD patients205. 
BAFF B cell activating factor belonging to the TNF family (BAFF) is a 
member of the TNF ligand superfamily. BAFF is a key regulator of 
immunoglobulin class-switch recombination and B lymphocyte 
development, survival, proliferation and maturation206. BAFF is produced, 
by bronchial and nasal epithelial cells206. Levels of BAFF protein are 
significantly increased in BAL fluid after allergen challenge in allergic 
subjects206. An overproduction of BAFF in nasal polyps has also been 
observed in patients with CRSwNP207.  
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 AR CRSsNP CRSwNP Asthma COPD Refs 
IL-4 Increased Increased Increased Increased Increased 22;97;208-212 
IL-5 Increased Increased Increased Increased ? 9;22;209;210;212 
IL-9 Increased ? ? Increased Increased 190-192 
IL-12 Decreased Decreased/ Increased ? 
Decreased/ 
Increased Increased 
182;213-216
 
IL-13 Increased Increased Increased/ No difference Increased 
Not 
increased 
184;198;212;217-
221
 
IL-17 Increased in 
severe AR ? Increased Increased Increased 
183-185;187
 
IL-18 Increased ? ? Increased/ Decreased Increased 
184;222-224
 
IFN-γ Decreased Increased Decreased Decreased Increased 
28;184;198;208;225
;226
 
IL-1β Increased Increased Increased Increased Increased 28;208;227 
IL-6 Increased Increased Increased Increased Increased 
184;209;213;227-
232
 
TNF-α Increased Increased Increased Increased Increased 
11;28;208;227;230;
232-235
 
TSLP Increased ? Increased (mRNA) Increased Increased 
200;202-205
 
GM-CSF Increased Increased Increased Increased Increased 11;236-239 
TGF-β Increased/ Decreased Increased Decreased Increased Increased 
28;198;208;240-246
 
IL-
8/CXCL8 Increased Increased Increased Increased Increased 
28;136;144;208;217
;227;230;231;233
 
IL-10 Increased/ Decreased ? ? 
Decreased/ 
Increased Decreased 
182;184;217;247;24
8
 
Table 5: Cytokines in upper and lower airway diseases 
    
 
 
 
CONCLUSION 
In conclusion, this report is reviewing the extensive data related on immune 
defence mechanisms operating in upper versus lower airways, as well as on 
their changes in chronic airway disorders. In particular, it is very likely that 
the airway epithelium plays a crucial role in key steps of chronic respiratory 
diseases, both during their development and natural history. 
Many similar features can be found between upper and lower airway, e.g. 
patterns of inflammation in diseases such as type 2 (Th2) cell activation in 
CRSwNP and asthma and type 1 (Th1) in CRS and COPD, while 
proinflammatory cytokines such as TNF-α and IL-6 may amplify the 
inflammatory reaction and thereby determining disease severity.  
However, several differences in immune and structural responses may be 
observed: 
First, frontline defence molecules of innate immunity may vary between 
upper and lower chronic airway diseases; these include lactoferrine which is 
decreased in CRSsNP while increased in asthma and COPD (unknown in 
AR and CRSwNP) - differences have also been reported for lyzozyme, 
annexins, and SPLA2 (Table 4). 
Second, mucosal associated lymphoid tissue is only present in upper 
airways under normal conditions, maybe in relation to the abundant 
presence of commensal bacteria that may provide signals to drive such 
immune orgnanisation and function; in contrast BALT seems to develop 
only upon pathological immune responses to foreign or endogeneous 
molecules (e.g. COPD, rheumatoid bronchiolitis). 
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Third, activation pathways leading to synthesis of growth factors such as 
TGF-β, EGFR ligands and/or VEGF, and/or the tissue reactivity and 
activation through their receptors, may vary between the nose and bronchi – 
and may be differently modulated by each other (e.g. TGF-β - EGFR 
crosstalk)249 - and could explain that structural remodelling during 
chronic/repeated epithelial damage predominantly occurs in lower airways. 
Fourth, clinical translation of inflammatory responses may vary between 
upper and lower airway levels according to the intrinsic function and/or 
structure of the airway, e.g. mucosal blockade due to vasodilation in the 
nose versus bronchospasm in the bronchi. 
Further investigations are needed to better understand how the genetic 
background may imprint both immune and structural reactivity to inhaled 
materials in upper and lower airways, and to underlie e.g. increased 
susceptibility to inhaled allergens and/or biotoxics notably at the level of 
dendritic cells and the epithelium, and how this integrates the structural 
remodelling of the respiratory mucosa that is characteristic of chronic 
airway diseases. 
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Objectives of the thesis 
The specific objectives of the thesis were:  
1. To assess whether the expression of pIgR/SC is reduced in CRSsNP, 
as compared to CRSwNP, AR and controls, and whether this change 
induces reduced IgA levels in mucosal secretions. The two 
subclasses of IgA were assessed, as well as specific IgA antibodies 
to relevant bacterial antigens such as S. pneumoniae and S. aureus. 
These changes were correlated to eosinophilic and T cell-driven 
inflammatory features. 
 
2. To assess whether the upper airway epithelium undergoes 
dedifferetiation in CRSwNP as a feature underlying pIgR 
downregulation, and whether this is associated with epithelial-to-
mesenchymal-transition and changes in lineage specification into 
goblet or ciliated cells. These findings were also correlated to 
subepithelial airway fibrosis and disease severity. 
 
3. To assess whether secretory IgA responses in CRSwNP could be 
restored by therapies such as anti-IgE and anti-IL5 biotherapies or other 
anti-inflammatory treatments  (corticosteroids, doxycycline). We 
assessed IgA antibodies in samples from CRSwNP patients included in 
placebo-controlled trials performed at the UZ Gent (Pr Ph Gevaert) for 
omalizumab, mepolizumab, doxycycline, and methylprednisolone, as 
compared to baseline and placebo.  
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MEDIATED SECRETORY IMMUNOGLOBULIN A PRODUCTION 
IMPAIRED IN CHRONIC UPPER AIRWAY DISEASES? 
 
 
    
 
 
 
Chapter 2: Is polymeric immunoglobulin receptor (pIgR)-mediated 
secretory immunoglobulin A production impaired in chronic upper 
airway diseases? 
 
INTRODUCTION 
The nasal mucosa is exposed to a large variety of inhaled microorganisms 
and antigens, and early recognition of antigen products in this region is 
critical for host defense. 
As a protective mechanism, a major function of mucosal epithelial cells is 
the transport of dimeric immunoglobulin A (IgA) into external secretions. 
IgA is commonly recognized as the most prevalent antibody subclass at 
mucosal sites, with various functional attributes, both direct and indirect, 
that serve to prevent infective agents such as bacteria and viruses from 
breaching the mucosal epithelial barrier. High affinity IgA antibodies play a 
critical role in protective adaptive immunity by neutralizing microbial toxins 
and pathogens, while ‘low affinity’ IgA antibodies represent a high capacity 
innate, frontline defence system, by preventing commensal bacteria from 
breaching the mucosal surface1.  
Mucosal secretions contain mainly dimeric IgA. Plasma cells in the lamina 
propria secrete dimeric IgA (dIgA), which structurally consist of two IgA 
monomers joined with the J-chain in a “tail-to-tail” conformation.  
To pass through the mucosal epithelial cells in order to enter the lumen, IgA 
requires a specific receptor for polymeric Igs called polymeric Ig receptor 
(pIgR), an integral membrane glycoprotein selectively expressed on the 
basolateral side of epithelial cells in the gut, bronchi and nasal mucosa. 
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Dimeric IgA is actively transported by the pIgR, which, thereby, plays an 
intrinsic role in protecting the respiratory tract from invading pathogens. 
After transcytosis, IgA is released at the apical surface after endoproteolytic 
cleavage of the pIgR extracellular domain or secretory component (SC) that 
bounds to dimeric IgA to form secretory IgA (s-IgA) and protects the 
molecule from proteolysis within the mucus2,3. SC displays itself, 
independently from IgA, some anti-infectious properties1. 
The specific humoral local defense is mostly mediated by s-IgA which is the 
most abundant Ig isotype in nasal secretions. S-IgA is involved in both 
innate and adaptive immunity and plays a crucial role in the first line of 
defense of the respiratory tract.1 S-IgA is mainly produced as an “innate” Ig 
upon mucosal stimulation by microbial signals acting through Toll-like 
receptors on epithelial cells and B cells4 while some IgA is produced as 
high-affinity antibody to particular antigens. 
This transcytosis of the pIgR/IgA complex represents the most important 
transcellular routing in the body.  
Several pathways may upregulate pIgR expression and/or transcytosis, 
including pro-inflammatory cytokines (IFN-γ, IL-4, TNF-α, IL-1), 
hormones and phorbol esters via various transcriptional and post-
transcriptional mechanisms5,6. The expression of polymeric 
immunoglobulin receptor (pIgR) is also known to be increased in response 
to viral or bacterial infections, linking innate and adaptive immunity.  
    
 
 
 
 
Figure 1 : pIgR and sIgA in the respiratory epithelium  
Dimeric IgA (dIgA) is secreted by the plasma cells of the lamina propria. It binds to the 
pIgR at the basolateral pole of secretory epithelial cells. dIgA is transported through the 
epithelial cell to the apical surface, where a proteinase cleaves the large extracellular 
domain of the receptor, thereby releasing it, bound to dIgA, into the lumen. dIgA, in 
association with the cleaved receptor fragment (also known as secretory component, SC) 
form sIgA. In secretions, sIgA interacts with antigens/pathogens, neutralizing their ability 
to cause disease. 
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Local production of IgA in the sinonasal mucosa is well established since 
the early sixties7,8. However, very few has been published regarding IgA in 
different sinonasal pathologies.  Bass et al. studied the localization and 
production of IgA in nasal mucosa and nasal polyps using 
immunofluorescent techniques9. They showed that bright staining IgA 
plasma cells localized around glandular elements were secreting their 
immunoglobulin contents into the gland lumens, with no difference in the 
localization or production of IgA between control nasal mucosa or nasal 
polyps. Van Zele et al. showed high levels of IgA in tissue homogenates 
from patients with CRSwNP, not correlated with serum IgA, suggesting a 
local production10. Similarly, Tan et al. showed an increase of total IgA 
levels in nasal polyp tissue extract relative to levels seen in CTRL nasal 
tissue extracts11. However, it remains unclear whether this increased IgA 
production translates into increased levels into sinonasal secretions. 
Another study has shown an increase of specific IgA level in lavage fluid in 
patients with allergic rhinitis to Dermatophagoides pteronyssinus after nasal 
allergen provocation12. An increased expression of IgA receptors on 
eosinophils of allergic individuals has also been reported13. At the contrary, 
Hsin et al. examined the levels of S-IgA and total IgA in patients with 
allergic rhinitis, patients with chronic rhinosinusitis and control subjects, 
and showed no difference among the 3 groups14. 
The expression of pIgR/SC has been mainly studied in lower airway 
diseases. It is strongly decreased in severe chronic obstructive pulmonary 
disease (COPD)2,15, correlated with airflow obstruction and associated to 
neutrophilic inflammation as neutrophil-derived proteinases are very potent 
to cleave both cell pIgR and soluble SC. The expression of pIgR/SC has 
    
 
 
 
also been shown to be decreased in lung cancer16. In the upper airways, 
pIgR has been studied in patients with nasopharyngeal carcinoma, where it 
has been shown to be decreased17 or mutated18, with resultant decreased 
transcytosis of IgA, but little is known regarding its role in chronic 
sinonasal pathologies. 
Because the upper and lower airways are linked physically, there has been 
an assumption that known defense mechanisms from the lower airways 
could be found also in the upper airways.   
In contrast to the well-documented reduced epithelial expression of SC in 
COPD and lung cancer, this first line of defense of the respiratory tract 
mechanisms is virtually unexplored in chronic upper airway diseases.  
The first part of this work concentrates thus on one of the first-line defense 
mechanisms of the airways, namely the S-IgA system, with a specific focus 
on its receptor, pIgR, and on the mucosal IgA response observed in chronic 
sinonasal diseases. 
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Downregulation of polymeric immunoglobulin receptor 
and secretory IgA antibodies in eosinophilic upper 
airway diseases 
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Abstract 
Background: Immunoglobulin (Ig) A represents a first-line defence 
mechanism in the airways, but little is known regarding its implication in 
upper airway disorders. This study aimed to address the hypothesis that 
polymeric Ig receptor (pIgR)-mediated secretory IgA immunity could be 
impaired in chronic upper airway diseases.   
Methods: Nasal and ethmoidal biopsies, as well as nasal secretions, were 
collected from patients with chronic rhinosinusitis (CRS) with (CRSwNP) 
or without nasal polyps (CRSsNP), allergic rhinitis (AR) and controls, and 
assayed for IgA1/IgA2 synthesis, pIgR expression, production of secretory 
component (SC), IgA and relevant IgA antibodies, and correlated to local 
eosinophils and inflammatory features (IL12, IL-13 and ECP). 
Results: pIgR expression was decreased in the ethmoidal mucosa in 
CRSwNP (p=0.003) and in AR (p=0.006). This pIgR defect was associated 
with reduced levels of SC (p=0.007) and IgA antibodies to Staphylococcus 
aureus enterotoxin B (SAEB) (p=0.003) in nasal secretions from CRSwNP 
patients, and with increased IgA deposition in subepithelial areas. pIgR 
    
 
 
 
downregulation was selectively observed in patients with tissue 
eosinophilia, whilst no clear relation to smoking history was observed. 
Conclusion: Epithelial pIgR expression is decreased in patients with 
CRSwNP and AR, and results in decreased SC and IgA antibodies to certain 
bacterial antigens (SAEB) in nasal secretions of CRSwNP patients in 
parallel to subepithelial accumulation of IgA. This defect in mucosal 
immunity is associated with eosinophilic, Th2-related inflammation.   
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Abbreviations:  
AR: Allergic rhinitis  
COPD: chronic obstructive pulmonary disease  
CRS: chronic rhinosinusitis 
CRSsNP: CRS without nasal polyps 
CRSwNP: CRS with nasal polyps 
ECP: eosinophil cationic protein 
Ig: immunoglobulin 
pIgR: polymeric Ig  receptor  
SA : Staphylococcus aureus 
SAEB : Staphylococcus aureus enterotoxin B 
S-IgA: secretory Ig A  
SC: secretory component  
    
 
 
 
INTRODUCTION 
Chronic rhinosinusitis (CRS) defines a group of disorders characterized by 
persistent inflammation of the sinonasal tract. The diagnosis is based upon 
the presence of persistent symptoms, nasal endoscopy and CT scan1. 
Depending on the presence of polyps on endoscopic examination, CRS is 
divided into 2 groups: CRS with (CRSwNP) or without nasal polyps 
(CRSsNP). Whereas the pathogenesis of CRS remains controversial, Th2-
driven eosinophilic inflammation is classically observed in CRSwNP, in 
contrast to CRSsNP where neutrophils are predominant. Allergic rhinitis 
(AR) represents another Th2-related nasal disorder. The role of pathogens, 
for both inception and exacerbations, is supported by several studies2, 3, 
whereas only a few report on defective defence mechanisms in these 
disorders4-6. 
Immunoglobulin (Ig) A is the predominant Ig in mucosal tissues, endowed 
with several protective functions such as neutralization of pathogens and 
particles7. At mucosal sites, plasma cells produce dimers of IgA, which are 
translocated across the epithelium from the lamina propria into mucosal 
secretions. This active transport is assumed by the polymeric 
immunoglobulin receptor (pIgR), expressed by epithelial cells, up to the 
apical pole where a proteolytic cleavage releases secretory IgA (S-IgA) 
consisting of d-IgA and the extracellular part of the pIgR known as 
secretory component (SC). This latter is thought to protect IgA from 
proteolysis and displays itself, independently from IgA, some anti-infectious 
properties.8 IgA is secreted via this route into the mucous lining fluid of the 
gastrointestinal, urogenital and respiratory tracts, as well as into tears, saliva 
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and milk9. pIgR expression and function is regulated through multiple 
pathogen-associated molecular patterns and pro-inflammatory cytokines 
such as IFN-γ, IL-4, TNF-α, and IL-1 via transcriptional and post-
transcriptional mechanisms10, 11. 
The expression of IgA and pIgR/SC has been mainly studied in the lung, 
where pIgR is decreased in severe chronic obstructive pulmonary disease 
(COPD) and in lung cancer.7, 12 In the upper airways, pIgR is downregulated 
in patients with nasopharyngeal cancer, but little is known regarding IgA 
and pIgR expression in chronic inflammatory sinonasal pathologies.13, 14  It 
has been shown that IgA is increased in tissue homogenates from patients 
with CRSwNP,15, 16 but it remains to determine whether this results into 
increased IgA in nasal secretions. We hypothesized that pIgR could be 
downregulated in CRSsNP, often seen as the upper airway equivalent of 
COPD, and could result in reduced secretion of pathogen-specific IgA 
antibodies. 
The aim of the present work was therefore to evaluate IgA synthesis and 
pIgR/SC expression in human nasal and sinusal tissues from patients with 
CRSwNP, CRSsNP and AR, as compared with controls, and to assess in 
nasal secretions from these patients SC and IgA to relevant bacterial 
antigens (S. pneumoniae and S. aureus), as well as their relation to 
eosinophilic and Th1(IL12p35) or Th2 (IL13)-related inflammation.  
METHODS 
For details, refer to the online supporting information section. 
 
    
 
 
 
Subjects and surgical sampling 
Patients with CRSsNP (n = 13), CRSwNP (n = 10), AR (n = 13) and 
controls (n = 20) were recruited at the outpatient clinic of our Department of 
Otorhinolaryngology (Cliniques Universitaires Saint-Luc, Belgium). The 
diagnosis of CRSwNP and CRSsNP was, accordingly to  EPOS criteria, 
based on history, clinical examination, nasal endoscopy and CT scanning1. 
AR was diagnosed based on symptoms and positive skin prick tests and/or 
serum specific IgE (> 0.35 kU/L) to common aeroallergens, following the 
ARIA guidelines17. Clinical characteristics of the patients are described in 
Table 1. Controls and AR patients underwent surgery for anatomical 
obstruction, whilst CRS patients underwent surgery as indicated by the 
disease. All patients were weaned of oral and nasal corticosteroids or 
antibiotics for at least 3 weeks before surgery.  
 Controls CRSsNP CRSwNP AR 
N 20 13 10 13 
Sex (M/F) 13/7 8/5 8/2 8/5 
Age, years (range) 38.6 (18-62) 35.7 (18-51) 48.2 (28-70) 35.4 (20-48) 
History of asthma 1 0 3 2 
Atopy 0 0 5 13 
Smoking 4 (20%) 4 (30%) 3 (30%) 3 (23%) 
CT score (Lund-
Mackay) 
1 (0-2) 12 (7-21)*** 18 (14-24)*** 1 (0-2) 
Serum IgA (mg/dl) 228 (89-633) 233 (113-485) 207 (97-367) 185 (173-289) 
 
Table 1. Patients characteristics. 
Patients were assigned to disease groups based on criteria described in Methods, and 
associated features (asthma, atopic background, cigarette smoking) are stated. *** p < 
0.0001 (Mann-Whitney U test) for CT scores, as compared to control subjects. 
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Sinonasal biopsies were taken from the inferior turbinate and anterior 
ethmoidal sinus. Nasal secretions were collected as previously described18 
for assessments of soluble factors including IgA and SC. Biopsies were 
processed for immunohistochemistry or PCR. Serum was also sampled to 
measure serum IgA. 
All subjects gave signed informed consent, and the study was approved by 
the local ethical committee (Cliniques Universitaires Saint-Luc, Brussels).   
 
Staining for pIgR, IgA and eosinophils 
Paraffin-embedded sections of turbinal and ethmoidal tissues were 
incubated with rabbit anti-human SC IgG  prepared as previously reported19 
and mouse anti-human IgA (ThermoScientific). To quantify pIgR and IgA 
staining, immunostained sections were scanned and analyzed using the 
Framework for Image Dataset Analysis (FrIDA).20 The percentage of 
stained area was calculated in 10 epithelial (pIgR) or subepithelial (IgA) 
fields, at x400 magnification, and reported to the surface of examined area. 
Eosinophils were counted after hematoxylin & eosin staining in 10 
epithelial fields, at x400 magnification. The presented data consists of the 
mean number of eosinophils per high power (x400) field. 
Quantitative RT-PCR for pIgR, IgA1, IgA2 and cytokines 
Two biopsies per patient (1 ethmoidal, 1 turbinal) were processed for gene 
expression by RT-qPCR. The expression levels of pIgR, IL12p35 and IL13 
in sinonasal tissue were quantified by RT-qPCR using the iCycler IQ5 PCR 
thermocycler (Bio-Rad, USA) and reported to those of RPS18 housekeeping 
gene. Absolute quantification of IgA1 and IgA2 expression levels was 
    
 
 
 
determined with RT-qPCR using an ABI PRISM 7900 Sequence Detection 
System thermal cycler according to manufacturer’s instructions (Applied 
Biosystems, USA).  
Immunoassays for IgA, SC, and ECP 
Concentrations of IgA, SC, IgA1, IgA2, specific IgA antibodies to 
pneumococcal anticapsular and S. aureus enterotoxin B (SAEB) antigens 
were determined in nasal secretions by ELISA. Eosinophil cationic protein 
(ECP) was measured by ImmunoCAP (Thermofisher) following 
manufacturer’s instructions. 
Statistical analysis 
Data are expressed in dot plots and presented as median and interquartile 
range. Statistical analysis was performed by the Kruskal–Wallis and Mann–
Whitney U two-tailed tests for unpaired comparisons. When multiple 
between-group comparisons were made, the Kruskal–Wallis test was used 
to establish the significant intergroup variability, and the Mann–Whitney U-
test was then used for between-group comparisons. Data were correlated by 
the Spearman rank test. A P level < 0.05 was considered as significant.  
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RESULTS 
pIgR expression in the sinonasal mucosa 
pIgR mRNA expression was decreased in the ethmoidal mucosa from 
CRSwNP and AR patients, when compared to controls (Figure 1A), whilst 
it was not reduced in CRSsNP. No significant change in sinonasal pIgR 
expression was observed in relation to cigarette smoking (not shown).  This 
downregulation in pIgR transcription was only observed in the ethmoidal, 
and not in the turbinal mucosa from these patients. 
At the protein level, pIgR immunodetection was confirmed in ciliated and 
seroglandular cells from the surface epithelium and submucosal glands 
(Figure 1C). No staining was found in basal cells and in goblet cells. 
Quantification of pIgR protein confirmed a significant reduction in 
CRSwNP and AR (Figure 1B).  
Total IgA and SC in nasal secretions and sinonasal mucosa 
 
We assessed whether pIgR downregulation resulted in decreased IgA levels 
in nasal secretions and sinonasal mucosa.  
First, SC concentration in nasal secretions was accordingly reduced in 
CRSwNP (Figure 1D) and correlated with tissue pIgR mRNA levels (Figure 
1E). 
In order to assess each compartments of the airway mucosa, we evaluated 
IgA content in sinonasal tissue by IgA immunostaining.  A significant 
    
 
 
 
accumulation of IgA was observed in subepithelial areas of ethmoidal tissue 
from CRswNP (Figure 2A). 
IgA synthesis was then assessed by RT-qPCR for IgA1 and IgA2 transcripts 
in sinonasal tissues, which showed no significant changes among the 
different groups (Figure 2B). Similarly, levels of IgA and IgA subclasses in 
nasal secretions were not significantly affected (Figure 2C). Of note, serum 
IgA was not significantly different among the groups (Table 1).  
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Figure 1: pIgR/SC expression in patients with upper airway disease. pIgR mRNA 
expression (A) in the ethmoidal mucosa from patients with CRSwNP, CRSsNP and AR, as 
compared to controls. pIgR protein detected by IHC was quantified in sinonasal tissue (B) 
and  is shown (C) in tissue from one representative control and one representative 
CRSwNP patient, as compared to negative control with rabbit IgG (left, medium and right 
panel, respectively). Secretory component (D) production in nasal secretions. Correlation of 
pIgR mRNA expression in the ethmoidal mucosa to SC in nasal secretions according to 
Spearman’s method (E). Bar represents 50µm. P values according to Kruskal-Wallis 
followed by Mann-Whitney tests.   
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Figure 2: IgA expression in patients with upper airway disease. IgA detected by IHC is 
shown in tissue from one representative control and one representative CRSwNP patient, as 
compared to negative control with mouse IgG (upper left, right and lower left panel, 
respectively), and was quantified in subepithelial areas (A). IgA1 and IgA2 mRNA 
expression (B) in the ethmoidal mucosa from patients with CRSwNP, CRSsNP and AR, as 
compared to controls. IgA1, IgA2 and total IgA (C) in nasal secretions from the same 
patient groups as shown in Figure 1. P values according to Kruskal-Wallis followed by 
Mann-Whitney tests.  
 
Specific IgA antibodies in nasal secretions 
We next assessed specific IgA antibodies to S. pneumonia and S. aureus 
antigens. Whereas non-significant changes were observed for S. 
pneumoniae, SAEB-specific IgA was significantly decreased in nasal 
secretions from patients with CRSwNP (Figure 3).  
  
Figure 3: Specific IgA antibodies to S. aureus and S. pneumonia antigens in patients 
with upper airway disease. Specific IgA antibodies to pneumococcal anticapsular antigens 
and to Staphylococcus aureus enterotoxin B (SAEB) in nasal secretions from the same 
patient groups as shown in Figure 1. Results are expressed in arbitrary units. P values 
according to Kruskal-Wallis followed by Mann-Whitney tests.   
    
 
 
 
pIgR expression and eosinophilic inflammation of the sinonasal mucosa 
As pIgR/SC and SAEB-IgA were decreased in CRSwNP, which is 
reportedly associated with eosinophilic inflammation, we addressed the 
relation between pIgR downregulation and eosinophilic inflammation in our 
patients.  
Increased numbers of eosinophils were observed, as expected, in 
subepithelial ethmoidal tissues from patients with CRSwNP (Figure 4A). 
Eosinophils were also observed in a subset of patients with CRSsNP. 
When dichotomizing patients according to the presence or not of high 
eosinophil numbers (i.e.  ≥2 versus <2 eos per h.p. field), pIgR 
downregulation was selectively observed in patients with eosinophilic upper 
airway disease (Figure 4B). In order to further assess a correlation between 
eosinophils and pIgR expression, ECP was measured in nasal fluid. ECP 
was significantly increased in patients with AR, but not CRSwNP (Figure 
4C), and no correlation was observed with pIgR expression (p= 0,5; r= -
0.1). 
 
Cytokine expression in the sinonasal mucosa 
IL-13 mRNA was significantly increased in the ethmoidal mucosa of 
CRSwNP, as well as to a lower extent in CRSsNP (Figure 4D). IL-
13mRNA was correlated to eosinophil numbers in ethmoidal biopsies 
(p=0.001, r=0.48), indicating a Th2-related immune response.  
In contrast, IL12p35 expression was only increased in the ethmoidal mucosa 
of CRSsNP patients (Figure 4E). In addition, IL-12p35 mRNA was 
correlated with pIgR expression (Figure 4E, right panel).  
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Figure 4: Eosinophils, ECP and and expression of IL-13 and IL-12 in patients with 
upper airway disease. Eosinophils (expressed as n cells per h.p. field) in the ethmoidal 
mucosa from patients with CRSwNP, CRSsNP and AR, as compared to controls (A), and 
pIgR expression is shown in these patients plotted as ‘eosinophilic’ (≥2 eos per h.p. field) 
versus low/non eosinophilic (<2) (B). Production of ECP in nasal fluid (C), and expression 
of IL-13 mRNA (D) and IL-12p35 mRNA (E)  in the ethmoidal mucosa from with 
    
 
 
 
CRSwNP, CRSsNP and AR, as compared to controls, and correlation with pIgR mRNA 
(right panel) according to Spearman’s method. P values according to Kruskal-Wallis 
followed by Mann-Whitney tests.   
DISCUSSION 
 
This study is, to our knowledge, the first to investigate epithelial pIgR in 
human chronic inflammatory disorders of the upper airways. It shows that 
the local expression of pIgR is downregulated in patients with CRSwNP and 
AR, but not in CRSsNP. This epithelial defect in CRSwNP resulted in the 
accumulation of IgA in subepithelial tissue (while active synthesis of IgA1 
and IgA2 was unaffected) and in reduced SC and SAEB-specific IgA 
antibodies in nasal secretions. Moreover, correlation to immuno-
inflammatory features highlighted that whilst pIgR positively correlates to 
IL-12 expression as Th1 signature, pIgR downregulation was closely related 
to Th2-type eosinophilic inflammation of the ethmoidal mucosa. 
In the upper airways, pIgR has been studied in nasopharyngeal carcinoma, 
where it has been shown to be decreased or mutated, with resultant 
decreased transcytosis of IgA13, 14. Our data show that pIgR is well detected 
in the human sinonasal epithelium. Contrary to our original hypothesis, 
pIgR was selectively downregulated in the ethmoidal tissue of CRSwNP 
and AR, and was not affected in the turbinal mucosa. We also showed that 
pIgR defect results into reduced secretion of SC in CRSwNP. In contrast, 
the tissue content of IgA was increased in subepithelial areas from patients 
with CRswNP, while active synthesis was not affected. These findings 
indicate that increased IgA content reported in previous studies of tissue 
homogenates from patients with CRSwNP15 does not relate to increased IgA 
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production but probably to the aborted IgA transport into secretions due to 
impaired epithelial pIgR expression. 
The pIgR defect in CRSwNP resulted in very modest and not significant 
reduction in IgA(2) in nasal secretions. However, levels of IgA antibodies to 
SAEB were significantly reduced in nasal secretions from these patients. 
Thus, as the pIgR assures the transport of IgA irrespectively of its 
specificity, its reduced expression in the ethmoidal epithelium from 
CRSwNP is not sufficient to drive significant decreases in “total” IgA, 
although a trend was observed (Figure 2C), in contrast to secretory 
component which was clearly decreased. IgA in secretions may arise 
locally, from synthesis by local plasma cells and subsequent pIgR-mediated 
transport, but also from exudation from the systemic circulation. As 
CRSwNP is associated with intense local inflammation and edema, we 
hypothesize that the latter element may “restore” the IgA levels in secretions 
from these patients, but does not compensate for reduced transport of locally 
produced IgA antibodies to S. aureus enterotoxin. An alternative possibility 
for the apparent discrepancy between reduced levels of SAEB-specific IgA 
and preserved levels of total IgA could lie in a specific defect in the 
generation of IgA antibodies to SAEB, which appears less likely. 
The finding of a defect in specific IgA immunity to this S. aureus 
superantigen is interesting considering the probably important role of SAEB 
in driving IgE-mediated inflammation in CRSwNP, where a proTh2 role of 
SAEB has been identified.21 Given the major role of IgA in frontline 
defence of the airways, including inhibition of the adherence of pathogens 
to the epithelium (so-called “immune exclusion”) and  neutralization of  
pro-inflammatory cytokines such as CXCL8/IL-8, it may be speculated that 
    
 
 
 
reduced pIgR-mediated immunity could affect first line and specific 
immunity in (eosinophilic) CRS and AR, favoring bacterial colonization and 
leading to a vicious circle of impaired anti-bacterial immunity and 
secondary chronic inflammation8, 22. The higher colonization by S. aureus in 
CRSwNP could be partly explained by decreased specific IgA to SAEB, as 
IgA plays an important role as a local scavenger of inhaled antigens. 
Moreover, IgA antibodies may probably also act as scavengers for allergens, 
which are reportedly defective in patients with AR and upregulated 
following allergen-specific immunotherapy23. This post-immunotherapy 
IgA response was shown to be selective for the IgA2 subclass and induced 
monocyte IL-10 secretion, whilst inhibiting IL-12 expression23,24. In 
addition to Fab-mediated antigen neutralization, a defect in S-IgA 
antibodies could also result in reduced (Fc-mediated) opsonisation of 
pathogens. As a defect in the phagocytosis capacity of macrophages from 
CRSwNP patients has been observed6, it remains to explore whether 
reduced cytophilic S-IgA antibodies could contribute to this observation. 
Moreover, interplay between S. aureus and ECP  has been recently 
observed, i.e. for the regulation of receptor for advanced glycation end 
products25. Our data further support a relationship between eosinophilic 
inflammation and local immunity to pathogen-derived products. Although 
balanced  by the known degranulating effect of secretory IgA on 
eosinophils, these mechanisms could further indicate that IgA contributes 
via several pathways to control mucosal inflammation26. 
In the lung, pIgR deficiency has been observed in the bronchial epithelium 
from smokers who developed severe COPD, and linked to neutrophil 
infiltration of submucosal glands7, 12. In contrast, our data show that pIgR 
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downregulation is not clearly related to smoking but rather to eosinophilic 
inflammation.  Eosinophilia was as expected a common feature in 
CRSwNP, but was also observed in some CRSsNP patients27-29. We 
observed that tissue eosinophils were more discriminant than the upper 
airway disease group, in identifying patients with pIgR downregulation, 
suggesting that this pIgR defect closely relates to eosinophilic inflammation. 
In contrast, a significant correlation was found between pIgR and IL12p35 
expression. As IL-12 is a key cytokine for the induction of IFN-γ-producing 
Th1 cells, this observation could be consistent with the known stimulatory 
role of IFN-γ on pIgR synthesis.30 However, it has been shown that IL-4 
may also upregulate pIgR transcription, in synergy with IFN-γ.31 As 
eosinophilic upper airway disorders are associated with Th2-type immune 
responses, it could be speculated that besides IL-4 other Th2-related factors 
could drive pIgR downregulation. Thus, our positive correlation between 
pIgR expression and IL-12 may suggest that, in addition or alternatively to 
favoring eosinophilic inflammation by limiting the scavenging effect of IgA 
antibodies to bacterial (super) antigens, pIgR downregulation could also 
result from the effect of mediators of Th2-type eosinophilic inflammation. 
Although this needs to be confirmed, notably using nasal epithelial cells, the 
putative pathways linking pIgR downnregulation and eosinophilic upper 
airway disease are summarized in Figure 5.  
Altogether this study shows for the first time that pIgR is well expressed in 
the human sinonasal mucosa, especially in seroglandular and ciliated 
epithelial cells, and that its expression is decreased in patients with 
CRSwNP and AR. This defect results in reduced secretion of SC and 
specific IgA antibodies to SAEB in nasal fluid from patients with CRSwNP, 
    
 
 
 
as well as in subepithelial accumulation of IgA. These data also indicate a 
previously unrecognized link between eosinophilic inflammation and pIgR-
mediated secretory immunity, suggesting that pIgR impairment is observed 
in the eosinophilic phenotype of upper airway disease. 
 
Figure 5: Putative pathways linking decreased pIgR expression and eosinophilic 
inflammation in CRSwNP. The proposed mechanisms underlying the relationship 
between pIgR-dependent IgA immunity and eosinophilic inflammation of the upper 
airways, include  decreased pIgR expression resulting in reduced IgA-mediated 
neutralization of some pathogens and/or antigens (e.g., S. aureus enterotoxin B), and in turn 
favoring eosinophilic inflammation (e.g. favored by SAEB-IgE). Conversely, it may also 
result from the effect of local mediators of eosinophil/Th2-related airway inflammation on 
the sinonasal epithelium.  
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Supporting information 
Downregulation of polymeric immunoglobulin receptor and secretory 
IgA antibodies in eosinophilic upper airways diseases 
Methods 
Immunohistochemistry for pIgR and IgA 
After surgical removal, the turbinal and ethmoidal biopsies were 
immediately immersed in 4% formaldehyde in phosphate-buffered saline at 
pH 7.4 for at least 24 h. Samples for immunohistology were embedded 
under vacuum in paraffin. Serial sections of 5 µm thickness were cut from 
paraffin blocks, spread on polylysine-coated glass slides, and dried at 40° C 
for at least 24 h.  
The slides were then processed for immunostaining, each step of the 
procedure being followed by washing with Tris-buffered saline (pH 7.4). 
After disembedding and rehydration of the specimen, endogenous 
peroxidases were inhibited by incubation in 0.03% (vol/vol) H2O2 in water 
for 30 min, and the slides were treated with 1% (wt/vol) BSA in Tris-
buffered saline for 30 min to neutralize remnant reactive aldehyde groups 
originating from fixation. Slides were then incubated overnight at 4° C with 
rabbit anti-human SC IgG  prepared as previously reported1 and mouse anti-
human IgA (ThermoScientific). Control sections were treated with rabbit 
anti-chicken IgY/mouse IgG at the same dilution. The secondary antibody, 
(biotinylated goat anti-rabbit IgG (Sigma, 1/1000), biotinylated rabbit anti-
mouse IgG (Sigma, 1/3000) was applied in 10% (wt/vol) defatted dry milk 
    
 
 
 
for 30 min. The reaction was amplified with streptavidin–peroxidase 
conjugate (BD Pharmingen, 1/500) in Tris-buffered saline containing 1% 
BSA for 30 min, and color was developed by incubation with 
diaminobenzidine in 0.03% H2O2 for 10 min. After the reaction was stopped 
by washing in water, slides were counterstained with Mayer's hemalum and 
mounted with coverslips in Eukitt's medium. Images of each section were 
captured by using an Aperio ScanscopeAT scanner.  
To assess pIgR and IgA quantification, unmodified images of scanned 
turbinal and ethmoidal sections were analyzed using the Framework for 
Image Dataset Analysis (FrIDA), a custom open source image analysis tool 
from the Johns Hopkins University, as previously described.16 Briefly, color 
masks were generated to identify DAB brown. A meta mask created to 
include all brown pixels in the epithelial (pIgR)/subepithelial (IgA) zone 
was used to analyze each image. We calculated the percentage of positive 
area fraction in ten epithelial/ subepithelial fields per section, at x400 
magnification.  
RT-PCR for pIgR, IL12p35, IL-13 and IgA1/IgA2 mRNA expression 
Total RNA was isolated using the Rneasy® Plus Mini kit (Qiagen). Each 
500 ng of total RNA was reverse- transcribed with RevertAidTM Reverse 
transcriptase kit (Fermentas) with 0.3µg of random hexamer (Invitrogen) 
and 1mM of each dNTP (Invitrogen) following to the manufacturer’s 
protocol in a thermocycler (Applied Biosystem). The expression levels were 
quantifed by real time quantitative PCR with the iCycler IQ5 PCR (Bio-
Rad). The reaction mix contained 5 µl of cDNA diluted 10-fold, 400nM of 
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each primer (pIgR reverse: CAG CCG TGA CAT TCC CTG ; pIgR 
forward: CTC TCT GGA GGA CCA CCG T ; RPS18 reverse: TGA TCA 
CAC GTT CCA CCT CAT ; RPS18 forward: TGT GGG CCG AAG ATA 
TGC T; IL-13 forward: CTG GAA TCC CTG ATC AAC GT . IL-13 
reverse: GAA AAC TGC CCA GCT GAG AC) and 2x iQTM 
SYBR®Green Supermix (Bio-Rad) in a final volume of 20µl. The cycling 
conditions were 95°C for 3 min followed by 40 cycles of 95°C for 15s and 
60°C for 30s. To control the specificity of the amplification products, a 
melting curve analysis was performed. Moreover, the negative controls 
(water and –RT) showed no amplification. Samples were run in duplicate 
and the copy number was calculated from a standard curve. The standard 
curve and data analysis were produced using Bio-Rad iQ5 Software.  
For IgA1 and IgA2, PCR was performed by using an ABI PRISM 7900 
Sequence Detection System thermal cycler according to manufacturer’s 
instructions (Applied Biosystems, Life Technologies Corporation, 
California, USA) using the equivalent of 1.25ng reverse transcribed RNA 
per reaction. Gene specific primer/probe sets were designed using the on-
line Universal ProbeLibrary Assay Design Centre (Roche Applied Science, 
Burgess Hill, UK). Universal ProbeLibrary probes were purchased from 
Roche Applied Science and corresponding forward and reverse primers 
synthesized by Sigma (Sigma-Aldrich Company Ltd, Dorset, UK). The 
primer/probes sets were as follows: IgA1, Forward-CAT 
GCCACGTGAAGCACTAC, Reverse-GGTAGGTGGAGTTGAGGGAAC 
T, Probe-UPL Probe 20; IgA2, Forward-CGCCAACATCACAAAATCC, 
Reverse-CGTCACCAGCTCGTTCAG, Probe-UPL Probe-17.  
    
 
 
 
SDS software was used to determine the absolute quantification of the target 
cDNA. Standard curves were created using plasmids containing cDNA for 
IgA1, I.M.A.G.E cDNA clone 4701069 and IgA2, I.M.A.G.E cDNA clone 
4765168 (Source Bioscience UK Limited, Nottingham, UK). 
ELISA for SC and IgA 
SC, IgA, IgA1 and IgA2 concentration were determined in nasal secretions 
by a specific enzyme-linked immunosorbent assay (ELISA). Briefly, 96-
well microplates were coated with 1 µg/ml affinity-purified goat anti-SC 
antibody (developed in our laboratory, recognizing both soluble SC and 
membrane pIgR/SC) in 0.1 M carbonate-bicarbonate buffer, pH 9.6, 
overnight at 4°C. After washings with 1/1.000 vol/vol Tween 20-PBS 
(PBST) and blockade with 1% wt/vol BSA in PBST for 1h at 37°C, samples 
and serial dilutions of purified human soluble SC/IgA1/IgA2 were 
incubated for 2 h at 37°C. After washings with PBST, plates were then 
incubated with biotinylated goat anti-SC/ biotinylated mouse anti-IgA1/ 
biotinylated mouse anti-IgA2 for 2 h and washed in TBST. A volume of 
100 µl streptavidin–polyHRP in a 1:10.000 dilution in HPE buffer was 
added to each well and incubated for 30 min at room temperature. The 
plates were washed three times using PBST, and 100 µl of (3,5,3′,5′)-
Tetramethylbenzidine substrate was added to each well. After incubation, 
the reaction was stopped by the addition of 100 µl of 2 M H2SO4. The 
absorbance was measured at 450 nm. 
Total IgA concentration was determined by the same method (coating with 
1 µg/ml affinity-purified goat anti-SC antibody, blockade with 1% wt/vol 
BSA in PBST, samples and serial dilutions purified total IgA) except for the 
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secondary antibody which was anti-human IgA (α-chain 
specific)−peroxidase antibody produced in goat. As it was peroxidase-
conjugated, use of streptavidin–polyHRP was not necessary.  
To assess specific IgA to pneumococcal anticapsular antigens and 
Staphylococcus aureus enterotoxin B, the same method was used, adapted 
from a previous report.2 Microplates were coated with the whole 23-valent 
pneumococcal polysaccharide vaccine (Sanofi-Pasteur MSD) or with 
Staphylococcal Enterotoxin B from Staphylococcus aureus (Sigma-Aldrich). 
The detection antibody was HRP-conjugated goat anti-human IgA (α-chain 
specific). Results were expressed as arbitrary units, by reference to serial 
dilutions of a highly positive sample (OD given by 1:2 dilution set as 1 unit, 
and corrected to the dilution factor). 
Immunoassay for ECP 
Quantification of ECP was carried out on nasal fluid samples by 
ImmunoCAP assay (Thermofisher), according to the manufacturer’s 
instructions. 
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CHAPTER 4 : DOES THE SINONASAL EPITHELIUM UNDERGOES 
DE-DIFFERENTIATION IN CHRONIC UPPER AIRWAY DISEASES 
AND, IF SO, IS IT ASSOCIATED WITH EMT AND CHANGES IN 
LINEAGE SPECIFICATION?
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INTRODUCTION 
Does the sinonasal epithelium undergo de-differentiation in chronic 
upper airway diseases and, if so, is it associated with EMT and changes 
in lineage specification? 
In the previous chapter, we thus showed that pIgR was downregulated in 
CRS. In parallel, our group showed that this pIgR expression is intimately 
related to epithelial differentiation1. Indeed, in COPD, it has been shown 
that reduced pIgR expression is secondary to altered epithelial cell 
differentiation and could lead to defective mucosal immunity, potentially 
contributing to a pathologic cycle of chronic airway inflammation and 
progressive remodeling2. 
As it is also known that remodeling is another major feature of CRS3, 4, we 
thus wondered whether pIgR downregulation could be due to a 
dedifferentiation of the upper airway epithelium, involving the activation of 
the epithelial-mesenchymal trophic unit, which controls the local tissue 
microenvironment. 
It is known that nasal epithelial repair is a well-coordinated and highly 
organized process, involving cell proliferation, differentiation and matrix 
degradation and deposition, regulated by a wide variety of growth factors and 
cytokines5. In-vivo and in-vitro studies showed that, during normal 
epithelial turnover and repair, undifferentiated basal cells (BC) 
progressively differentiate into ciliated and goblet cells (CC and GC), to 
reconstitute a functional respiratory epithelium6, 7. Wound healing may 
either restore the epithelium ad integrum or induce remodeling of the 
    
 
 
 
airways, resulting in chronic inflammation and altered differentiation8. The 
first step of the repair process requires loss of differentiation (or de-
differentiation), spreading, and migration of airway epithelial cells from the 
edges of the wound9, while the second step is epithelial redifferentiation into 
CC or GC. 
One of the best examples of cell de-differentiation is epithelial-to-
mesenchymal transition (EMT), which has been observed in epithelial 
tissues in response to stress or injury, contributing to fibrosis in the 
kidney,10 liver,11 and lung12 both in human and animal models. 
 
What is EMT? 
From a general perspective, epithelial-mesenchymal transition (EMT) is 
about disaggregating epithelial units and reshaping epithelia for 
movement13. More specifically, EMT is a biologic process that allows 
polarized epithelial cells, which normally interact with basement membrane 
(BM) via their basal surface, to undergo multiple biochemical changes that 
enable them to assume a mesenchymal cell phenotype, which includes the 
lost of cell-cell polarity and adhesion, resulting in enhanced migratory 
capacity, the downregulation of junction proteins and the modulation of 
their cytoskeleton organization, with acquisition of vimentin filaments13.  
EMT is an essentiel mechanism during embryonic development, as without 
mesenchymal cells, tissues and organs would never be formed. EMT is 
required for gastrulation and morphogenesis of the neural crest, 
musculoskeletal system, craniofacial structures, and peripheral nervous 
system14. The epithelium can also undergo EMT in adult physiological 
EMT in chronic upper airway diseases 
133 
 
processes, such as wound healing15 or inflammation16, leading to fibroblast 
production and fibrogenesis. Finally, EMT occurs in neoplastic cells, in the 
context of tumor growth and cancer progression17.  
One of the main distinguishing characteristics of EMT is the loss or down-
regulation of adherens junctions and cytokeratin intermediate filaments. 
The adherens junction complex of epithelial cells, which show disturbed 
localization in some inflammatory conditions, serve as an important 
paracellular barrier in polarized epithelial cells.18 As the airway epithelium 
is the natural barrier between the environment and underlying tissue, its 
integrity is important for protecting the airways against noxious inhalants, 
such as environmental tobacco smoke, particles and biological agents. 
Damage to respiratory epithelium is known to contribute to the pathogenesis 
of airway diseases through the alteration of barrier function and 
permeability of the mucosa.19 Therefore, regulation of cell–cell junction 
stability and dynamics is crucial to maintain tissue integrity and allowing 
tissue remodelling throughout development. The cadherin family, among 
others, mediates cell-cell adhesion. E-cadherin is one of the best-
characterized adherens junctions expressed on nasal epithelium.  
A defective epithelial barrier was found in patients with AR after Der p 1 
antigen exposure along with a decreased expression of tight junctions 
proteins, contributing to increased epithelial permeability and representing 
thereby a potential mechanism for transepithelial antigen exposure in AR20. 
A disruption of epithelial integrity with reduced expression of tight 
junctions protein has also been shown in CRSwNP 21-23. 
Vimentin is the most ubiquitous intermediate filament protein and the first 
to be expressed during cell differentiation. All primitive cell types express 
    
 
 
 
vimentin but in most non-mesenchymal cells, other intermediate filament 
proteins replace it during differentiation. 
The up-regulation of vimentin expression is a particularly wellknown 
marker of the EMT, and even appears to be a prerequisite for EMT 
induction.Vimentin contributes to EMT via upregulating the gene 
expression of several EMT-linked genes24. Only a few studies have been 
published regarding vimentin in chronic upper airway diseases. Its presence 
is confirmed in sinonasal mucosa from control and CRS patients25. Meng et 
al. showed a trend to a higher, although non-significant number of 
vimentin+ cells in the turbinate part of nasal polyps, as compared to normal 
nasal mucosa22.  
Epithelial cells undergoing EMT thus change their intermediate filament 
status from a keratin-rich network that connects to adherens junctions, to a 
vimentin-rich network connecting to focal adhesions. Concretely, they lose 
epithelial makers, such as E-cadherin and cytokeratins, but express 
mesenchymal markers, such as vimentin. 
This process has been widely described in pathologic conditions of the lung, 
such as lung fibrosis12 or obliterans bronchiolitis26 whilst it remains debated 
in COPD27 and asthma28.  
Emerging evidence suggests that the upper airway epithelium also could 
contribute to airway remodeling through the process of EMT. The aim of 
this second chapter was thus to describe more specifically the changes that 
the upper airways epithelium undergoes in terms of terminal and lineage 
differentiation during chronic sinonasal disesaes, in order to better 
understand the mechanisms leading to inflammation and remodeling. 
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Figure 1 Major features of epithelial and mesenchymal cells. Epithelial cells contain 
specialized junctional proteins, exhibit apico-basal polarity, and have limited potential for 
dissociation and migration. In contrast, mesenchymal cells do not form specialized 
adhesion complexes and are irregular in shape with end-to-end polarity and focal adhesions 
resulting in increased migration capacity. During EMT, epithelial cells gain mesenchymal 
features which include changes in the expression of epithelial and mesenchymal markers  
(from Lee and Nelson, New Insights into the Regulation of Epithelial–Mesenchymal 
Transition and Tissue Fibrosis, Int Rev Cell Mol Biol. 2012;294:171-221.) 
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Features of mesenchymal transition in the airway 
epithelium from chronic rhinosinusitis  
Cloé Hupin, Sophie Gohy, Caroline Bouzin, Marylène Lecocq, Myriam 
Polette, Charles Pilette. Allergy. 2014 Nov;69(11):1540-9 
Abstract 
Background: Chronic rhinosinusitis (CRS) defines a group of disorders 
characterized by persistent inflammation of the sinonasal tract. Epithelial 
changes and structural remodelling are present, but whether epithelial 
differentiation is altered remains uncertain. 
Methods: To evaluate the differentiation state of the sinonasal epithelium in 
CRS, sinonasal biopsies from patients with CRS with (CRSwNP) or without 
polyps (CRSsNP), or with allergic rhinitis (AR), as compared to controls, 
were processed by immunohistochemistry and RT-qPCR for terminal 
differentiation (E-cadherin, high molecular weight cytokeratins (Hmw CK) 
and CK5, vimentin) and lineage differentiation (ß-tubulin IV+ ciliated cells, 
MUC5AC+ goblet cells, p63+ basal cells). Findings were correlated to 
subepithelial fibrosis and clinical CT score. 
Results: Expression of E-cadherin was decreased at protein and mRNA 
levels in CRSwNP and CRSsNP, as compared to controls. Staining for Hmw 
CKs was also reduced in CRSwNP and CRSsNP, and CK5 mRNA was 
decreased in CRSwNP. These features were not due to changes in lineage 
specification, but associated with increases in vimentin-expressing epithelial 
    
 
 
 
cells. In addition, vimentin expression correlated with the basement 
membrane thickening and with CT score, as well as with tissue eosinophils. 
Conclusion: Features of epithelial de-differentiation towards a 
mesenchymal phenotype are observed in CRSwNP and CRSsNP, and 
correlate with airway fibrosis and inflammation. 
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Abbreviations:  
AR: allergic rhinitis 
BCs: basal cells 
BM: basement membrane 
CCs: ciliated cells 
CK: cytokeratin 
COPD: chronic obstructive pulmonary disease 
CRS: chronic rhinosinusitis 
CRSsNP: chronic rhinosinusitis without nasal polyps 
CRSwNP: chronic rhinosinusitis with nasal polyps 
Hmw CK: high molecular weight cytokeratins  
Ig: immunoglobulin 
IL: interleukin 
RT-qPCR: real time quantitative polymerase chain reaction  
    
 
 
 
INTRODUCTION 
Chronic rhinosinusitis (CRS) is defined as a chronic inflammation of the 
nose and the paranasal sinuses, characterized by persistent symptoms and 
typical features at nasal endoscopy and CT scan1. CRS has been typically 
divided into CRS with nasal polyps (CRSwNP) and without nasal polyps 
(CRSsNP) based on the presence or not of polyps on endoscopic 
examination, and differ from allergic rhinitis (AR), which represents another 
very common chronic nasal disease2. 
Besides inflammation, these chronic upper airways disorders are 
characterized by remodelling of structural components, especially of the 
epithelium. The upper airway epithelium provides both a physical and 
chemical barrier through the formation of a strong mechanical cohesion by 
apical (tight and adherens) junctions and by secretion of a large array of 
antimicrobial host defense molecules mediating innate immunity 
respectively. Tissue remodelling in upper airways is an active process that 
includes increased extracellular matrix deposition, with subepithelial 
basement membrane (BM) thickening3. 
The normal upper airway epithelium comprises three main cell types, 
namely ciliated cells (CCs), representing 50% to 90% of the airway 
epithelial cell population4, 5, mucus-secreting goblet cells (GCs) and basal 
cells (BCs). BCs represent 6 to 30% of the epithelial population in the lower 
airways and are considered as stem cells6. GCs and CCs act in concert to 
support mucociliary clearance and remove inhaled potentially harmful 
substances. Changes in epithelial specification have been described in 
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chronic airway diseases and following injury. Thus the number of CCs is 
decreased in asthma7, after a viral infection8 or in response to environmental 
toxics such as cigarette smoke9. In contrast, changes in these epithelial 
lineages remain unclear in CRS, with controversial findings reported in 
CRSwNP and CRSsNP regarding MUC5AC expressing GCs10, 11. One study 
also reported increased BC numbers in CRSwNP12. 
Besides commitment of epithelial cells to ciliated or goblet phenotypes, 
terminal differentiation is critical to epithelial homeostasis. Upon injury, 
epithelial cells may de-differentiate through squamous metaplasia or so-
called epithelial-to-mesenchymal transition (EMT), which describes a rapid 
and normally reversible modulation of the epithelial phenotype towards 
mesenchymal cells13. Epithelial cells undergoing EMT are losing cell-cell 
polarity and adhesion to become migratory, and usually downregulate 
junctional proteins (such as E-cadherin) whilst modulating their 
cytoskeleton organization and acquiring mesenchymal features such as 
vimentin filaments. EMT occurs during development and normal wound 
repair, while deregulated EMT may occur during cancer metastasis. In 
addition, it is increasingly recognized that chronic inflammation resulting 
from repeated injury may also induce persistent EMT, thereby contributing 
to tissue fibrosis14. In the upper airways, downregulation of tight junction-
related proteins has been recently described in CRSwNP15-17, whereas it 
remains unclear whether this relates to dedifferentiation of the sinonasal 
epithelium through EMT. 
The aim of this study was to evaluate whether the sinonasal epithelium 
undergoes de-differentiation in CRS and, if so, its relation to lineage 
    
 
 
 
specification and to EMT. Findings were also correlated to airway 
remodeling and clinical CT score. 
 
MATERIAL AND METHODS 
Additional supporting information may be found in the online version of 
this article. 
Subjects and surgical sampling 
Patients with CRSsNP (n = 11), CRSwNP (n = 11), AR (n = 10) and 
controls (n = 13) were recruited at the outpatient clinic of our Department of 
Otorhinolaryngology. The diagnosis of CRSwNP and CRSsNP was, 
accordingly to EPOS criteria, based on history, clinical examination, nasal 
endoscopy and CT scanning1. AR was diagnosed based on symptoms and 
positive skin prick tests and/or serum specific IgE (> 0.35 kU/L) to common 
aeroallergens, following the ARIA guidelines2. Clinical characteristics of 
the patients are described in Table 1. Controls and AR patients underwent 
surgery for anatomical obstruction, whilst CRS patients underwent surgery 
as clinically indicated. All patients were weaned of corticosteroids or 
antibiotics for at least 3 weeks before surgery, and underwent a preoperative 
CTscan as part of the clinical work-up, which was graded according to the 
Lund-Mackay score18. 
Biopsies from inferior turbinates (AR and controls) and from ethmoidal 
mucosa (CRS) were processed for immunohistochemistry or RT-qPCR. 
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An informed consent was obtained from each subject, and the study was 
approved by the local ethical committee (Cliniques Universitaires Saint-
Luc, Brussels, Belgium). 
 Controls CRSsNP CRSwNP AR 
N 13 11 11 10 
Sex (M/F) 11/2 7/4 9/2 7/3 
Age, years (range) 36.4 (18-62) 37.2 (20-51) 48.2 (28-73) 35.2 (20-48) 
History of asthma 1 0 3 1 
Atopy 0 0 4 10 
Smoking 4 (30%) 4 (36%) 4 (36%) 3 (30%) 
CT score 1 (0-2) 12 (7-21)** 17(14-23)*** 1 (0-2) 
 
    
 
Table 1. Patient characteristics.Patients were assigned to disease groups based on criteria 
described in Methods, and associated features (asthma, atopic background, cigarette 
smoking) are stated. Asthma diagnosis was based on the report of typical symptoms and 
lung function tests, according to GINA33, and atopy was defined by the presence of skin-
prick test or serum IgE responses to at least one common aeroallergen. ** p<0.01, *** 
p<0.0001 (Kruskal-Wallis test followed by Dunn post hoc test) for CT scores (Lund-
MacKay), as compared to control subjects. 
Immunohistochemistry for epithelial differentiation and phenotyping 
Five-µm sections of turbinal and ethmoidal biopsies were stained for E-
cadherin and Hmw CK as epithelial markers and for vimentin as 
mesenchymal marker. Lineage markers comprised p63, MUC5AC and ß-
tubulin IV for BCs, GCs and CCs, respectively. To quantify the epithelial 
markers, immunostained sections were scanned using a SCN400 scanner 
(Leica) and analyzed using TissueIA software (SlidePath). Counting of 
    
 
 
 
vimentin-expressing columnar cells was carried out manually by a blinded 
observer (CH). Serial stainings for vimentin and CD45 allowed confirming 
the presence of vimentin-expressing epithelial cells, in addition to 
intraepithelial leukocytes (Figure E1). Five random epithelial fields were 
examined per slide, at high magnification (x400). Data are reported for all 
patients, except when tissue and/or epithelial areas were not sufficiently 
preserved. BM thickness was measured by multiple point-to-point repeated 
measurements, as previously described19. 
Quantitative RT-PCR for E-cadherin, CK5, vimentin, ß-tubulin IV, 
MUC5AC and p63 gene expression 
In order to confirm the staining for epithelial markers, mRNA expression 
levels were quantified in sinonasal tissue and normalized to GAPDH 
housekeeping gene by using the UPL-probe system (Roche Diagnostics, 
Basel, Switzerland).  
Statistics 
Statistical analyses were performed using IBM SPSS Statistics 21.0 (SPSS, 
Inc, Chicago, USA) and figures were designed using GraphPad Prism 5.00 
(GraphPad Software, San Diego, USA). Results are shown as scatter dot 
plots with mean and standard deviation. Normality was assessed for each 
data set. For non-parametric data, Kruskal-Wallis test followed by Dunn 
post hoc test were carried out for multiple comparisons. Mann-Whitney U 
test was used for the analysis of differences between 2 groups of unpaired 
data. Normal data were assessed by one-way Anova followed by Tukey 
post-hoc test for multiple comparisons. Correlation coefficients were 
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calculated using Spearman's rank method. P-values <0.05 were considered 
as statistically significant. 
 
RESULTS 
Decreased expression of epithelial cadherin and keratins in CRS 
To assess the differentiation state of the sinonasal epithelium, tissue sections 
of control subjects, CRSsNP, CRSwNP and AR patients were first 
immunostained for E-cadherin and Hmw CK (Figure 1A). E-cadherin was 
significantly decreased in patients with CRSsNP (p = 0.03) and CRSwNP (p 
= 0.02), when compared to controls (Figure 1B). Similarly, Hmw CK 
expression was decreased in CRSsNP (p = 0.04) and CRSwNP (p = 0.01), 
as compared to control subjects (Figure 1C). These results were confirmed 
by RT-PCR, showing decreased transcription of E-cadherin in CRSwNP 
and CRSsNP, while CK5 mRNA (a major Hmw CK, preferentially 
expressed by basal cells) was also significantly decreased in CRSwNP 
(Figure 1D). 
Number of ciliated and goblet cells are not significantly changed in CRS 
To address whether these epithelial changes related to changes in epithelial 
specification, numbers of CCs, GCs and BCs were evaluated in the CRS 
sinonasal epithelium by immunohistochemistry and RT-qPCR (Figure 2A). 
No significant changes were observed for β-tubulin IV + CCs and 
MUC5AC+ GCs, and this was confirmed at the mRNA level for these 
markers (Figure 2B-C). The number of p63+ BCs was decreased in 
    
 
 
 
CRSsNP, as compared to controls (p = 0.008) (Figure 2B), while this 
change was not observed at the mRNA level (Figure 2C).  
These data suggested that the epithelial de-differentiation may not be related 
to changes in the lineage specification of the upper airway epithelium. 
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Figure 1: Immunohistochemistry for epithelial markers in sinonasal tissue.  
A. Immunostaining for E-cadherin (left) and Hmw CK (CK50) (right) in sinonasal 
epithelium. Representative images from each group are shown (scale bar, 100µm).  
B. Quantification of E-cadherin staining using TissueIA software (SlidePath) (n= 45).  
C. Quantification of the Hmw CK staining using TissueIA software (SlidePath) (n=41).  
D. E-cadherine (left) and CK5 (right) mRNA expression in sinonasal mucosa from 
patients with CRSwNP, CRSsNP and AR, as compared to controls, and normalized to 
GAPDH housekeeping gene. 
Increased numbers of vimentin-expressing epithelial cells in CRS 
We then evaluated whether epithelial de-differentiation could relate to the 
acquisition of a mesenchymal phenotype, by assessing the number of 
vimentin positive epithelial cells in the sinonasal epithelium of our patients. 
The number of vimentin expressing epithelial cells was significantly 
increased in CRSsNP (p=0.001) and CRSwNP (p<0.0001), as compared 
with controls (Figure 3A-C). In addition, increased vimentin-expressing 
epithelial cell numbers correlated with the radiological (Lund-McKay) score 
(r = 0.59, p<0.0001) (Figure E2-C). It was also correlated with the number 
of eosinophils (r = 0.5, p =0.004) assessed in our previous study of the same 
series of patients20 (figure E2-A). 
Increased subepithelial fibrosis in CRS 
We then evaluated whether this EMT feature was associated with 
subepithelial fibrosis, by measuring the BM thickness in the same epithelial 
areas (Figure 3B). We observed increased BM thickness in CRSsNP (p = 
0.04) and CRSwNP (p = 0.01) (Figure 3D). In addition, BM thickening 
EMT in chronic upper airway diseases 
151 
 
correlated with the CT score (r = 0.48, p = 0.003) (Figure E2-D) and with 
vimentin-expressing epithelial cells (r = 0.54, p = 0.0001) (Figure 3F). 
Moreover, the BM thickness correlated with tissue eosinophilia (r=0.36, 
p=0.04) (Figure E2-B). 
    
 
 
 
 
Figure 2: Immunohistochemistry for different cell types in sinonasal tissue.  
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A. Immunostaining for p63 (basal cells, left), MUC5AC (goblet cells, middle) and ß-
tubulin IV (ciliated cells, right). Representative images from each group are shown 
(scale bar, 100µm). 
B. Quantification of p63 (n=42), MUC5AC (n = 36) and ß-tubulin IV (n=40) staining in 
sinonasal epithelium, expressed as percentage of positive cells (p63) and percentage of 
stained area (MUC5AC and ß-tubulin IV). 
C. p63, MUC5AC and ß-tubulin IV mRNA expression in sinonasal mucosa from patients 
with CRSwNP, CRSsNP and AR, as compared to controls, and normalized to GAPDH 
housekeeping gene. 
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Figure 3: Vimentin and fibrosis in sinonasal tissue.  
A. Immunostaining for vimentin in sinonasal epithelium. Representative images from 
each group are shown (scale bar, 100µm) (n=45).  
B. Evaluation of BM thickness; representative hematoxylin-and-eosin stained images 
from each group are shown. 
C. Quantification of vimentin staining in sinonasal epithelium (n=45), expressed as 
percentage of positive cells.  
D. Measurement of the BM height using TissueIA software (SlidePath) (n=45).  
E. Vimentin mRNA expression in sinonasal mucosa from patients with CRSwNP, 
CRSsNP and AR, as compared to controls, and normalized to GAPDH housekeeping 
gene. 
F. Correlation of vimentin expression to BM thickness. 
Discussion 
This study shows in a large series of well-characterized patients that the 
sinonasal epithelium undergoes de-differentiation in CRS, which does not 
relate to changes in lineage differentiation (CCs/GCs), but to mesenchymal 
transition. In addition, percentage of vimentin-expressing epithelial cells 
correlates with subepithelial fibrosis evidenced by BM thickness and with 
the disease severity (CT scoring), suggesting a role in disease pathogenesis.  
E-cadherin is a transmembrane glycoprotein that establishes and stabilizes 
cellular contacts in adherens junctions between adjacent epithelial cells. E-
cadherin is involved in the control of several aspects of epithelial 
homeostasis, including morphological differentiation, cell proliferation and 
cell motility, notably during wound healing and inflammation21. A defective 
epithelial barrier has been recently described in patients with CRSwNP, 
along with a decreased expression of tight junction proteins, such as 
claudin-4, occludin, zonula occludens-115, 16. We confirm a defect in 
    
 
 
 
junctional complexes, by showing decreased expression of adherens 
junction-associated E-cadherin in CRSwNP. In addition, this epithelial 
defect was also observed in CRSsNP, suggesting that this feature may occur 
in different phenotypes of chronic sinusal disorders. 
Our data suggest that EMT occurs in the upper airways of patients with 
CRS. In the lung, EMT has been shown in lung fibrosis14 and obliterans 
bronchiolitis22 and is debated in COPD23 and asthma24. During EMT, 
epithelial cells undergo phenotypic transition to mesenchymal cells, 
acquiring the intermediate filament vimentin in their cytoskeleton, 
subsequently become spindle shaped, and exhibiting front-to-back, leading-
edge polarity13. EMT has not been specifically studied in chronic sinonasal 
diseases. One previous study showed the presence of vimentin+ epithelial 
cells in both normal nasal mucosa and CRS, and suggested that these cells 
may arise from EMT25. A recent paper showed a trend to a higher, but not 
significantly, number of vimentin+ cells in the turbinate part of nasal 
polyps, as compared to normal mucosa16. Our study shows that the vimentin 
expression is increased in the epithelium from patients with CRSwNP and 
CRSsNP, as well as to a lesser extent (only at the transcriptional level) with 
AR. BM thickening has been described in asthma26, COPD27, and CRS28. 
Accordingly, we found a thickening of the BM in CRSsNP and CRSwNP, 
while clefts identified within the BM from COPD patients27 were not 
observed (not shown). The low number of vimentin-expressing epithelial 
cells may indicate that EMT selectively concerns certain cells and, although 
quantitatively limited, may reflect a profound reprogramming of the upper 
airway epithelium in CRS also characterized by the loss of junctional 
proteins (Figure 4). In addition, epithelial vimentin expression correlated 
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with BM thickening, and both vimentin and BM thickness correlated with 
the radiological score, suggesting that EMT correlates to disease severity in 
CRS and could contribute to its pathogenesis.  
 
 
Figure 4: Epithelial-to-mesenchymal transition in chronic rhinosinusitis 
De-differentiation and EMT features are observed in CRSwNP and CRSsNP, characterized 
by decreased expression of junctional proteins associated with tight and adherens junctions, 
increase of intracellular vimentin filaments, and thickening of the basement membrane. 
 
In contrast to these differentiation features, no significant change in lineage 
differentiation was observed in CRS when assessing the two main 
differentiated cell types, namely GCs and CCs5. BCs are relatively 
undifferentiated cells, considered as a multipotent progenitor population and 
a common feature of stratified and pseudostratified epithelia throughout the 
body6. During normal epithelial turnover and repair, they progressively 
differentiate into other cell types, such as GCs or CCs, reconstituting a 
functional respiratory epithelium6. An increase of BCs has been reported in 
    
 
 
 
CRSwNP12. In contrast, we observed a decrease in p63+ BCs in patients 
with CRSsNP, while p63 mRNA expression was not affected, and a 
decrease in mRNA expression of CK5 (a CK preferentially expressed by 
BCs, along CK14) in CRSwNP. It remains thus unclear whether BC 
numbers are contributing to epithelial changes. In addition, whereas mucus-
secreting GCs show varying density in the nasal mucosa (with a peak of 
10.000 cells/mm² in the maxillary sinus29) and changes in patterns of mucin 
gene expression11, 29, studies showed contradictory results with either a 
decrease11 or an increase10 of MUC5AC expression in CRSwNP. In our 
study, no significant change in the percentage of MUC5AC+ epithelial cells 
was observed. Similarly, no change was observed for ß-tubulin IV+ CCs, 
considered as terminally differentiated columnar cells, both at protein and 
mRNA levels. These data suggest that, although the number of BCs is 
probably highly variable according to the turnover of the upper airway 
epithelium and may be affected in CRS, the differentiation programming 
into the two main cell types (CCs and GCs) is preserved in CRS. 
In contrast, de-differentiation and EMT features were observed both in 
CRSwNP and CRSsNP. As these two disorders generally differ in terms of 
immune profile, this observation may indicate that these changes could 
occur independently of the nature of the inflammatory reaction. Similarly, 
EMT has been suggested in the bronchial epithelium both in asthma and 
COPD23, 24. However, we observed that vimentin expression correlated with 
tissue eosinophils. It is known that damage to the epithelium closely 
correlates with the degree of eosinophil infiltration, and that eosinophil 
products can cause epithelial damage and submucosal oedema30. Activated 
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eosinophils contribute to CRSwNP through the release of major basic 
protein in the production of cytokines31. It could therefore be speculated, 
although several pathways could be involved, that eosinophils may 
contribute to epithelial de-differentiation and EMT. Alternatively, epithelial 
dysfunction could favour eosinophilia through several mechanisms such as 
impaired exclusion of proeosinophilic superantigens from Staphylococcus 
Aureus32. We recently reported decreased levels of IgA antibodies to 
Staphylococcus Aureus enterotoxin B in the nasal fluid from patients with 
CRSwNP20, as the putative result of impaired pIgR expression in the 
sinonasal epithelium, which closely relates to epithelial differentiation 
(Gohy AJRCCM 2014 provisionally accepted on 30 July 2014). 
It is also very likely that EMT per se affects the epithelial barrier against 
pathogens, by defects in junctional complexes and in epithelial secretion of 
antimicrobial factors. 
In summary, our data indicate for the first time that epithelial de-
differentiation towards a more mesenchymal phenotype occurs in the upper 
airways of patients with CRSsNP and CRSwNP, independently of lineage 
differentiation into ciliated and goblet cells. This epithelial reprogramming 
correlates with subepithelial fibrosis and with disease severity. These 
findings also highlight common mechanisms of epithelial dysfunction 
between upper and lower airways, occurring during chronic inflammatory 
diseases. Future studies should address the underlying mechanisms, which 
could represent future therapeutic targets in CRS.  
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Supporting Information 
Methods 
Immunohistochemistry 
After surgical removal, the turbinal and ethmoidal biopsies were 
immediately immersed in 4% formaldehyde in phosphate-buffered saline at 
pH 7.4 for at least 24 h. Samples for immunohistology were embedded in 
paraffin. Serial sections of 5 µm thickness were cut from paraffin blocks, 
spread on Superfrost Plus glass slides, and dried at 40° C for at least 24 h. 
The slides were then processed for immunostaining, each step of the 
procedure being followed by washing with Tris-buffered saline (TBS) with 
0.05% Tween 20 (Sigma-Aldrich, Saint-Louis, USA) (pH 7.4) After 
deparaffinization and rehydration of the specimen, endogenous peroxidases 
were inhibited by incubation in 0.3% (vol/vol) H2O2 in water for 30 min. 
Antigen retrieval was performed in a citrate buffer during 75 minutes at 
98°C. A blocking step was then performed by incubating slides in 5% 
(wt/vol) BSA in TBS-Tween for 30 min and was followed by a 10 min 
incubation with avidin and biotin 0.001% to block endogeneous biotins. 
Slides were then incubated overnight at 4°C with primary antibody diluted 
in TBS-Tween containing 1% BSA followed by anti-mouse IgG (whole 
molecule)-biotin (Sigma-Aldrich, Saint-Louis, USA) applied in 2% (wt/vol) 
defatted dry milk for 30 min at RT. 
The reaction was amplified with streptavidin horseradish peroxidase 
conjugate (HRP) (BD Bioscience, San Jose, USA) in TBS-Tween 
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containing 1% BSA for 30 min, and revealed with Ultra View Universal 3, 
3-diaminobenzidine detection kit (Roche, Basel, Switzerland) according to 
manufacturer’s instructions. Slides were counterstained with Mayer's 
hematoxylin and mounted with Safemount medium. 
Immunostaining was performed following this protocol for anti- human E-
cadherin (clone NCH-38, DAKO, Glostrup, Denmark), anti-human Hmw CK 
(CK50, clone 34bE12, DAKO, Glostrup, Denmark), anti- human vimentin 
(clone V9, DAKO, Glostrup, Denmark), anti- human CD45 
(clones2B11+PD7/26, DAKO, Glostrup, Denmark), anti-human p63 (clone 
4A4 + Y4A3, ThermoScience), anti-human β-tubulin IV (clone ONS.1A6, 
Sigma-Aldrich, Saint-Louis, USA), anti-human MUC5AC (clone CLH2, 
Leica, UK) antibodies. Control sections were treated as appropriate with 
normal mouse IgG isotype at same dilution.  
Slides were scanned with a SCN400 scanner (Leica), calibrated for 
brightness and white balance. Stained areas over threshold were quantified 
within manually delineated epithelium, using TissueIA software 
(SlidePath). The threshold was established according to negative and 
positive controls. The same threshold was applied for all slides. 
Five random epithelial fields (x400 magnification) from each sample were 
analyzed. 
Results for E-cadherin, Hmw CK (CK50), MUC5AC and ß-tubulin IV were 
calculated and expressed as the percentage of positive/stained area within the 
epithelium, using TissueIA  software (SlidePath). P63 positive cells were 
calculated and expressed as percentage of stained cells per total cells in the 
epithelial field, using the same software. Vimentin positive cells were 
    
 
 
 
counted manually by a single blinded observer, reported to the total number 
of epithelial cells, and expressed as percentage of stained cells per epithelial 
field. A serial staining of vimentin and CD45 allowed us to exclude 
inflammatory cells that could also express mesenchymal markers. These 
inflammatory cells, even if positively stained, were not taken in account in 
the counting of vimentin positive cells.  
Quantification of the thickening of reticular basement membrane on vimentin 
staining pictures was performed by multiple point-to-point repeated 
measurements at regular intervals of 20µm on the same fields as for vimentin 
quantification (x400 magnification).  
 
Quantitative RT-PCR for ß-tubulin IV, MUC5AC and p63 
Total RNA was isolated using the Rneasy® Plus Mini kit (Qiagen). 500 ng 
of total RNA was reverse-transcribed into cDNA with RevertAidTM 
Reverse transcriptase kit (Fermentas, Vilnius, Lithuania). Vimentin, E-
cadherin, cytokeratin 5 (CK5), p63, ß-tubulin IV and MUC5AC expression 
were quantified and normalized to GAPDH by qPCR using the UPL-probe 
system (Roche Diagnostics, Basel, Switzerland). qPCR reactions were 
performed using the “Fast Start Universal Probe Master” kit as 
recommended by the manufacturer, in the LightCycler 480 Instrument 
(Roche Diagnostics). The reverse and forward primers (Eurogentec, 
Seraing, Belgium) for vimentin, E-cadherin, CK5, p63, ß-tubulin IV, 
MUC5AC and GAPDH were designed as follows: vimentin primers 
(Forward: GCG TGA CGT ACG TCA GCA ATA TGA, Rev: GTT CCA 
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GGG ACT CAT TGG TTC CTT), E-cadherin primers (For: GAC ACA 
TTT ATG GAA CAG AAA ATA ACA, Rev: AGT GGA AAT GGC ACC 
AGT GT), CK5 primers (For: TTC ATG AAG ATG TTC TTT GAT GC, 
Rev: AGG TTG CGG TTG TTG TCC), p63 primers (For: CGC CAT GCC 
TGT CTA CAA, Rev: TGA CTA GGA GGG GCA ATC T), ß-tubulin IV 
primers (For: CCG GAC AAC TTC GTG TTT G, Rev: ACA GCG TCC 
ACC AGC TCT), MUC5AC primers (For: CAC GTC CCC TTC AAT ATC 
CA, Rev: GGC CCA GGT CTC ACC TTT) and GAPDH primers (For: 
ACC AGG TGG TCT CCT CTG AC, Rev: TGC TGT AGC CAA ATT 
CGT TG). Each sample was quantified using a standard curve made of 
serial dilutions of a batch of human nasal polyp cDNA (made with the 
“Transcriptor First Strand cDNA Synthesis” kit-Roche).  
Additional figures 
 
Figure E1: Serial immunostaining (5µm between sections) for vimentin (left) and CD45 
(right). Red arrows show intraepithelial leukocytes that were not taken in account for 
vimentin quantification. Scale bar, 100µm. 
    
 
 
 
Figure E2: Correlations between epithelial vimentin expression, eosinophils, 
subepithelial fibrosis and clinical CT score of sinusitis. 
A. Correlation between vimentin-expressing epithelial cells and eosinophil numbers. 
B. Correlation between BM thickness and eosinophil numbers. 
C. Correlation between vimentin-expressing epithelial cells and Lund-McKay CT score. 
D. Correlation of BM thickness and Lund-McKay CT score. 
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CHAPTER 5: COULD STEROIDS AND IMMUNOGLOBULIN E- OR 
IL-5-TARGETED BIOTHERAPIES RESTORE SECRETORY IGA 
RESPONSES IN NASAL POLYPOSIS?
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ASSESSMENT OF S-IGA ANTIBODIES IN CRSWNP PATIENTS 
TREATED BY METHYLPREDNISOLONE, DOXYCYCLINE, 
MEPOLIZUMAB OR OMALIZUMAB, VS PLACEBO  
Introduction 
As we observed that pIgR expression is decreased in CRSwNP, including 
specific S-IgA antibodies to Stapylococcus Aureus along subepithelial IgA 
accumulation due to impaired pIgR-mediated transport, we thought to 
evaluate the effects of medical treatments of CRSwNP on IgA production in 
order to address the possibility that local inflammation could condition the 
airway epithelium for pIgR downregulation. This study was carried out in 
collaboration with Prof. Ph. Gevaert (Upper Airways Research Laboratory, 
UZ Gent) who kindly provided nasal and serum samples from different 
controlled trials performed in their department.  
IgA was assessed by ELISA in nasal secretions from CRSwNP patients 
treated by Doxycycline, Methylprednisolone, Mepolizumab or Omalizumab 
vs placebo.  
We present here the results of these investigations. 
Material and Methods 
ELISA for SC and IgA subclasses 
Total IgA, SC, IgA1, IgA2 and specific IgA to Staphyloccoccus Aureus 
enterotoxin B concentrations were determined in nasal secretions by a 
specific enzyme-linked immunosorbent assay (ELISA). For SC, IgA1 and 
IgA2, 96-well microplates were coated with 1 µg/ml affinity-purified goat 
anti-SC antibody (developed in our laboratory, recognizing both soluble SC 
    
 
 
 
and membrane pIgR/SC) in 0.1 M carbonate-bicarbonate buffer, pH 9.6, 
overnight at 4°C. After washings with 1/1.000 vol/vol Tween 20-PBS 
(PBST) and blockade with 1% wt/vol BSA in PBST for 1h at 37°C, diluted 
samples and serial dilutions of purified human soluble SC/IgA1/IgA2 were 
incubated for 2 h at 37°C. After washings with PBST, plates were then 
incubated with biotinylated goat anti-SC/ biotinylated mouse anti-IgA1/ 
biotinylated mouse anti-IgA2 for 2 h and washed in TBST.  
A volume of 100 µl streptavidin–polyHRP in a 1:10.000 dilution in HPE 
buffer was added to each well and incubated for 30 min at room 
temperature. The plates were washed three times using PBST, and 100 µl of 
(3,5,3′,5′)-Tetramethylbenzidine substrate was added to each well. After 
incubation, the reaction was stopped by the addition of 100 µl of 2 M 
H2SO4. The absorbance was measured at 450 nm. 
Total IgA concentration was determined by the same method (coating with 
1 µg/ml affinity-purified goat anti-SC antibody, blockade with 1% wt/vol 
BSA in PBST, diluted samples and serial dilutions of purified total IgA) 
except for the secondary antibody which was anti-human IgA (α-chain 
specific)−peroxidase antibody produced in goat. As it was peroxidase-
conjugated, use of streptavidin–polyHRP was not necessary.  
To assess specific IgA to pneumococcal anticapsular antigens and 
Staphylococcus aureus enterotoxin B, the same method was used, adapted 
from a previous report.1 Microplates were coated with the whole 23-valent 
pneumococcal polysaccharide vaccine (Sanofi-Pasteur MSD) or with 
Staphylococcal Enterotoxin B from Staphylococcus aureus (Sigma-Aldrich). 
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The detection antibody was HRP-conjugated goat anti-human IgA (α-chain 
specific). Results were expressed as arbitrary units, by reference to serial 
dilutions of a highly positive sample (OD given by 1:2 dilution set as 1 unit, 
and corrected to the dilution factor). 
Values obtained by ELISA were corrected with a dilution factor. 
Patients and study design 
All measures were realized on serum and nasal fluid samples collected 
during 3 different studies conducted by the Department of 
Otorhinolaryngology of the University Hospital in Ghent, Belgium2-4. Nasal 
fluid was collected as previously described (Watelet et al.)5. 
Subjects from Doxycycline-Methylprednisolone study (adapted from Van 
Zele et al.2) 
Fourty-six healthy patients with recurrent CRSwNP after surgery or massive 
CRSwNP were included. The use of systemic or local corticosteroids or 
antibiotics was not allowed during the study; if necessary, patients were 
permitted to use nasal corticosteroids as rescue medication 2 months after 
dosing with the study medication.  
Patients were randomly assigned to 3 groups : groups were given either oral 
methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 
mg/d on days 11-20, 14 subjects), oral doxycycline (200 mg on day 1, 100 
mg/d on days 2-20, 15 subjects), or placebo (lactose, 17 subjects) in 
unlabeled capsules. Follow-up visits were scheduled for 1, 2, 4, 8, and 12 
weeks after dosing. 
    
 
 
 
IgA measurements were realized on serum and nasal fluids samples 
collected at visit 1, 3 (after 4 weeks) and 4 (after 8 weeks). 
Subjects from Mepolizumab study (adapted from Gevaert et al.3) 
Twenty-seven subjects with primary CRSwNP (based on EPOS criteria) or 
CRSwNP recurrent after surgery were included. The inclusion criteria 
specified that subjects must have had failure of standard care for CRSwNP.  
Use of systemic corticosteroids and surgical intervention was not allowed 
from 1 month before treatment until the end of the study, and subjects were 
not permitted to use nasal corticosteroids, nasal antihistamines, nasal 
atropine, nasal cromolyn, nasal saline, or antibiotic treatment for 2 months 
after first dosing. A randomized, double blind, placebo-controlled study of 
mepolizumab was performed in patients with CRSwNP. After signing the 
informed consent form and a 4- to 12-week run-in period, subjects were 
randomized to receive 2 single intravenous injections (28 days apart) of 750 
mg of mepolizumab (18 subjects) or placebo (9 subjects). Follow-up visits 
were scheduled 1, 4, 8, 12, 24, 36, and 48 weeks after first dosing. During 
the follow-up visit after 4 weeks, the second injection of mepolizumab was 
administered. All randomized patients were included in the analysis. The 
study was double blind up to 48 weeks. 
IgA measurements were realised on serum and nasal fluids samples 
collected at visit 1, 3 (after 8 weeks) and 4 (after 12 weeks). 
Subjects from Omalizumab study (adapted from Gevaert et al.4) 
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Twenty-two subjects with CRSwNP (EPOS guidelines) and asthma (GINA 
guidelines) were included in the study. Their serum IgE levels were 
comprised between 30 and 700 kU/mL. All patients underwent skin prick 
tests and both allergic and non-allergic patients were included in the study. 
After a 2-week run-in period, subjects were randomized on a 2:1 basis to 
receive subcutaneous treatment with anti-IgE (14 subjects) or placebo (8 
subjects). Both the investigator and the subject were blind to study 
treatment. The dose (in milligrams) and dosing frequency (every 2 weeks/8 
injections in total or every month/4 injections in total) of omalizumab 
(Xolair; Novartis, Basel, Switzerland) were based on total serum IgE levels 
(in international units per milliliter) and body weight (in kilograms), with a 
maximum dose of 375 mg. After screening, 10 visits were scheduled every 
2 weeks over 20 weeks.  
IgA measurements were realized on serum and nasal fluids samples 
collected at visit 1, 4 and 6. 
Results 
In the three different studies, all previous mentioned IgA subclasses and SC 
were measured, however, in order to simplify the following chapter, only 
significant results are shown. 
1. Doxycycline-Methylprednisolone study 
a) Nasal secretions 
SC is increased in nasal fluid from CRSwNP patients one week after 
methyprednisolone treatment (p = 0.005), but this increase did not persist on 
the subsequent visit.  
    
 
 
 
Conversely, the level of SAEB-specific IgA was decreased 4 weeks after 
methyprednisolone treatment. 
 
b) Serum 
We observed no significant changes in IgA levels in the methyprednisolone 
group (vs placebo), except a minor decrease of IgA2 between visit 1 and 
visit 3 and between visit 1 and visit 4. 
 
Patients treated with doxycycline (as compared to placebo) showed no 
significant changes in IgA levels upon visit 3 and visit 4, neither in nasal 
secretions nor in serum.  
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2. Mepolizumab study 
a) Nasal secretions  
No significant effect of mepolizumab was observed vs placebo, except a 
decrease in total IgA after 4 weeks, which was associated with a large 
dispersion of values in the placebo group.  
 
b) Serum 
There was no change in serum IgA levels upon mepolizumab treatment vs 
placebo, while a very modest decrease was observed in IgA1 levels over time 
(4 weeks vs 1 week), as also seen for SEB-specific IgA.  
 
 
 
    
 
 
 
3. Omalizumab study 
a) Nasal secretions 
We observed reduced IgA1, IgA2 and SC production in nasal secretions from 
patients treated by omalizumab at visit 4 and 6. 
 
b) Serum  
No significant differences were observed among IgA levels in the serum of 
patients treated by omalizumab as compared to placebo. 
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Conclusions 
The main information about these results is thus that secretory component is 
increased in nasal secretions of CRSwNP patients treated by 
methylprednisolone, after one week of treatment, but that this effect does 
not persist with time. This increase in SC could be due to a higher turnover 
of pIgR and/or a higher expression of the receptor, influenced by 
methylprednisolone, as we showed previously that pIgR expression was 
downregulated in CRswNP patients. This unknown effect of 
methylprednisolone could contribute to the decrease of nasal symptoms 
observed in CRSwNP patients during methylprednisolone treatment, and to 
the rebound effect after the end of the treatment. 
However, these results must be confirmed, especially by prospective 
studies, where the impact of methylprednisolone could be studied on IgA 
and SC levels, but also on pIgR expression, and correlated to clinical 
symptoms. 
Other changes in IgA levels were either very modest and/or of uncertain 
clinical relevance. This could be due, in part, to the fact that samples had to 
be highly diluted to perform the ELISA assays, as IgA levels in nasal 
secretions were very high. As a consequence, these results need to be 
confirmed by other techniques, such as immuno-nephelometry or 
ImmunoCap, and correlated to the local expression of pIgR or IgA levels in 
biopsies or tissue homogenates. 
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General conclusions 
The main objective of this thesis was to investigate the secretory IgA system in 
chronic upper airway diseases, and its link with eosinophilic inflammation and 
epithelial changes.  
In the first study, we confirmed that, as described previously in COPD1, 
pIgR expression is reduced in CRSwNP and AR. This reduced expression 
results in reduced secretion of SC and specific IgA antibodies to SAEB in 
nasal fluid. IgA subclasses, however, were not significantly affected in nasal 
fluid, but accumulated at subepithelial level. We hypothesized that the 
increased IgA levels described in this work and, earlier, by Van Zele et al.2 
were thus a reflection of an aborted IgA transport into secretions due to 
impaired epithelial pIgR expression. Interestingly, similar results were 
published simultaneously by Hulse et al.3, confirming a reduced expression 
of pIgR in CRSwNP, with increased levels of IgA in tissue homogenates, 
but without significantly increased IgA levels in nasal lavage fluid. 
Contrarily to us, they hypothesized that these higher IgA levels in tissue 
were due to an increased IgA production, with a pIgR system unable to 
upregulate its function. In our views, IgA accumulation rather relates to 
impaired epithelial transport, as indices of active synthesis of IgA1 and IgA2 
were unchanged. 
Moreover, we showed that pIgR positively correlates to IL-12 expression as 
Th1 signature, but, most importantly, that pIgR downregulation is closely 
related to Th2-type eosinophilic inflammation. It has been postulated many 
years ago that IgA may be the principal Ig mediating eosinophil effector 
function at mucosal surfaces4. High quantities of IgA in the tissue might 
    
 
 
 
thus further exacerbate inflammation through degranulation of eosinophils, 
among other pathways.  
In the second study, we assessed epithelial changes in terms of lineage and 
terminal differentiation. We showed a decrease of terminal differentiation 
marker expression (E-caderin and Hmw CK) as well as an increase in 
fibrosis (vimentin expression and basal membrane thickening) in CRSwNP 
and CRSsNP, while the number of ciliated and goblet cells remained 
unaffected. This decrease in E-cadherin and cytokeratins, associated with an 
increase in vimentin, could be considered as the first signs of EMT in 
CRSwNP and CRSsNP. A reduction of E-cadherin and/or junctional 
proteins has been described previously in chronic upper airway diseases 5-8, 
but was not asssociated to a significant increase in vimentin.  
It is interesting that, as in asthma and COPD9, 10, EMT is present in 
CRSwNP and CRSsNP. This observation highlights two important points: it 
reinforces the already known link between upper and lower airways, and it 
might suggest that EMT is not directly related to a specific inflammatory 
profile. The increase in vimentin however, correlates to eosinophilic 
inflammation, independently of the disease. As epithelial damage is linked 
to eosinophilic infiltration11, we suggested that eosinophils might play a role 
in epithelial de-differentiation and EMT. It could also be hypothesized that 
EMT itself could induce a compromised mucosal epithelial barrier, as part 
of the epithelial cells differentiate into mesenchymal cells, reducing thereby 
their capacity to secrete protective molecules such as antimicrobial host 
defence molecules, cytokines and chemokines.  
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These results have been meanwhile confirmed at bronchial level in COPD 
patients, both in tissue and in broncho-epithelial cultures12. Our team 
showed a decrease of junctional proteins in COPD patients, while the 
number of vimentin cells was enhanced. We also showed an increase in the 
basal membrane height in these patients. These mesenchymal features are 
reactivated in vitro, and result at least in part from a reprogramming by 
TGF-β, as we showed that TGF-β promotes EMT in air-liquid interface 
broncho-epithelial cultures. 
EMT is known to be induced either by environmental factors such as 
repeated injury and cigarette smoke10 or extracellular mediators. Among 
them, TGF-ß1 is the key regulator of the remodeling pattern of CRS. TGF-β 
has been linked to COPD13 and its expression is increased in the COPD 
airway epithelium14. However, its role in CRS is controversial. Higher 
levels of TGF-ß1 characterize CRSsNP, while CRSwNP patients show 
lower levels of TGF-ß115. As EMT is present in both diseases despite their 
different expression of TGF-ß1, we speculate that other pathways may exist 
to induce EMT, and should thus be investigated in order to understand the 
regulatory mechanisms involved in epithelial plasticity and to provide 
specific treatments of these diseases. 
EMT is observed in both CRSwNP and CRSsNP, but pIgR is only 
significantly reduced in CRSwNP. We also observed no correlation between 
pIgR expression and EMT markers (vimentin upregulation, E-cadherin and 
HmwCK downregulation), suggesting that the pathways involved in both 
mechanisms are probably different. 
    
 
 
 
The strengths of this work rely on studies of well-characterized and 
carefully selected patients. Results are based on both nasal tissue and nasal 
secretions, and rely on protein and mRNA data. Previous studies in the field 
of upper/lower airway epithelium are reinforced and putative new 
mechanisms are suggested.  
We recognize, however, some limitations of the present work, especially in 
the fact that these data should be confirmed in vitro, in differentiated 
air/liquid epithelial cultures. Despite some efforts and expertise of the lab 
with bronchial epithelial cultures, we did not achieve convincing results 
regarding pIgR production by cultured nasal epithelial cells, suggesting that 
terminal epithelial differentiation may not have been reached in these 
conditions. 
Future directions of this work should thus include fully differentiated nasal 
epithelial cell culture, in order to address in vitro the effects of putative 
cytokines and eosinophils able to downregulate pIgR expression in chronic 
upper airway diseases. Regulation of pIgR expression and transcytosis of 
dimeric IgA across the epithelium (to generate secretory IgA at the apical 
pole) could be studied in this system, in response to factors that could 
directly affect pIgR expression;  among these candidates are Th2 cytokines 
such as IL-4, IL-9, IL-13, and local eosinophils. 
Another perspective could be to study the effects of therapies, especially 
methylprednisolone, on local IgA and pIgR expression, in prospective 
studies, as discussed in chapter 5, with correlation to clinical 
symptomatology. 
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Altogether, these two original studies shed new insights into the 
immunopathological pathways involved in CRS and might open 
possibilities for new therapeutic approaches in the treatment of these 
chronic upper airway diseases. 
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